**3. Overview of the hematopoietic niche**

Hematopoiesis is the process by which hematopoietic stem cells (HSCs) generate and replenish progenitors that develop into fully mature blood and immune cells, and populate the periphery. During vertebrate ontogeny, hematopoiesis is established sequentially in several different anatomic sites (see Development of Hematopoietic Stem Cells chapter in this book for review). Coincident with the onset of EO (approximately the last third of embryonic development), hematopoiesis shifts from the fetal liver and spleen to the EO-derived marrow, which represents the predominant site of blood cell production after birth (Aguila and Rowe 2005; Cumano and Godin 2007). Therefore, the marrow has become a tissue of study for hematopoietic cell biology post parturition. Additionally, due to the ease of marrow cell isolation in combination with the extensive list of cell markers identifying HSCs at different stages of differentiation (as summarized in (Morrison and Spradling 2008), stem cell niche biology has also utilized the marrow environment for study.

be appreciated by the orange staining of the cartilaginous core, with green-blue bone matrix deposited on the surface (magnification, 10x). C) The inorganic mineralized matrix of a mature zebra bone illustrates the structural differences between the EO-derived trabecular /spongy/cancellous bone and the IO-derived compact/dense/cortical bone. Boxed is a high magnification of the EO- and IO-derived bone tissues. Note the mesh-like structure of

Taken together, the proper differentiation of chondrocytes, vascular invasion and the gradual replacement of the cartilaginous anlagen by trabecular bone and marrow through EO, underscore the intricate orchestration of skeleto-hematopoiteic development. Moreover, the coincident establishment and localization of trabecular bone within the site of active hematopoiesis likely reflects a critical hematopoietic niche in the chondro-osseous region (**Fig. 1B boxed**) (Jacenko et al. 1993; Nilsson et al. 1997; Gress and Jacenko 2000; Nilsson et al. 2001; Jacenko et al. 2002; Yoshimoto et al. 2003; Arai, F. et al. 2004; Balduino et al. 2005; Sweeney et al. 2008; Kohler et al. 2009; Lo Celso et al. 2009; Xie et al. 2009; Sweeney et al. 2010). This skeleto-hematopoietic link is strongly supported by several animal models where alterations in process of EO leads to hematopoietic defects (**Table 1**), including mouse models with altered: collagen X (Jacenko et al. 1993; Gress and Jacenko 2000; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010), parathyroid hormone related protein (PTHrP) receptor in osteoblasts (Calvi et al. 2001; Calvi et al. 2003; Kuznetsov et al. 2004; Wu et al. 2008), osteoblast numbers (Visnjic et al. 2001; Visnjic et al. 2004; Zhu et al. 2007), bone morphogenic protein (BMP) receptor type 1A in marrow cells (Zhang, J. et al. 2003), osteoclast function (Blin-Wakkach et al. 2004; Mansour et al. 2011), retinoic acid receptor gamma (Purton et al. 2006; Walkley et al. 2007), Gs in ostoblasts (Wu et al. 2008), Dicer in ostoblasts (Raaijmakers et al. 2010), glypican-3 (Viviano et al. 2005), and perlecan (Rodgers et al. 2008). **Table 1** presents a list of mouse models with defects in hematopoiesis due to alterations in a component within the niche environment. Only those mouse models are summarized that were proven, by and large, via bone marrow transplantation experiments to have an aberrant niche environment, since wild type

trabecular bone for hematopoietic cell support.

marrow cells could not rescue the disease phenotype of the host.

Hematopoiesis is the process by which hematopoietic stem cells (HSCs) generate and replenish progenitors that develop into fully mature blood and immune cells, and populate the periphery. During vertebrate ontogeny, hematopoiesis is established sequentially in several different anatomic sites (see Development of Hematopoietic Stem Cells chapter in this book for review). Coincident with the onset of EO (approximately the last third of embryonic development), hematopoiesis shifts from the fetal liver and spleen to the EO-derived marrow, which represents the predominant site of blood cell production after birth (Aguila and Rowe 2005; Cumano and Godin 2007). Therefore, the marrow has become a tissue of study for hematopoietic cell biology post parturition. Additionally, due to the ease of marrow cell isolation in combination with the extensive list of cell markers identifying HSCs at different stages of differentiation (as summarized in (Morrison and Spradling 2008), stem cell niche biology has also utilized the marrow

**3. Overview of the hematopoietic niche** 

environment for study.


Table 1. Mouse models with altered hematopoetic niche enviroments.

Skeletogenesis and the Hematopoietic Niche 153

Table 1. continued


Table 1. continued

Table 1. continued


Table 1. continued

Skeletogenesis and the Hematopoietic Niche 155

The idea of a unique tissue environment, or stem cell niche, as a tissue setting that can direct progenitor cell behavior, e.g. quiescence, proliferation, differentiation, etc. was proposed over four decades ago (Wolf and Trentin 1968; Trentin 1971; Schofield 1978; Wolf 1979). Hematopoietic niches, or hematopoietic microenvironments (HME), are defined by the association of particular cell types, their secreted matrix products and their soluble hematopoietic factors (Yin and Li 2006; Rodgers et al. 2008). The identity of the cellular, matrix and soluble components that influence HSCs, including the long-term populating (LT-HSC), short-term populating (ST-HSC), or the more differentiated hematopoietic progenitor cells (HPC), as well as the lymphoid and myeloid lineages, remains an active topic of investigation. However, at least two hematopoietic niches have been described, an osteoblastic (or endosteal) niche, ascribed to osteoblasts residing on bone surfaces, and a vascular niche, ascribed to endothelial cells and subendothelial MSCs or pericytes lining marrow sinusoids. Many have argued that more quiescent LT-HSCs and ST-HSCs are located in the osteoblast niche, while differentiating HPCs are located in the vascular niche for mobilization to the periphery (Lord et al. 1975; Shackney et al. 1975; Gong 1978; Nilsson et al. 2001; Heissig et al. 2002; Arai, F. et al. 2004; Balduino et al. 2005; Jang and Sharkis 2007; Bourke et al. 2009). However, these regions in the marrow are so close in proximity (Arai, F. et al. 2004; Kiel et al. 2005; Lo Celso et al. 2009; Xie et al. 2009), that the osteoblast and vascular niches may be the same, or perhaps interchangeable to some degree. Additionally, recent work has identified other cells involved in hematopoiesis that do not fully comply with these proposed niche regions, such as CXC chemokine ligand (CXCL)-12 expressing reticular cells that are scattered throughout the marrow (Tokoyoda et al. 2004; Sugiyama et al. 2006; Omatsu et al. 2010). Below we will discuss the different cellular, matrix and soluble components within the marrow that have

Table 1. continued

been shown to influence hematopoiesis.


Table 1. continued

Table 1. continued


#### Table 1. continued

The idea of a unique tissue environment, or stem cell niche, as a tissue setting that can direct progenitor cell behavior, e.g. quiescence, proliferation, differentiation, etc. was proposed over four decades ago (Wolf and Trentin 1968; Trentin 1971; Schofield 1978; Wolf 1979). Hematopoietic niches, or hematopoietic microenvironments (HME), are defined by the association of particular cell types, their secreted matrix products and their soluble hematopoietic factors (Yin and Li 2006; Rodgers et al. 2008). The identity of the cellular, matrix and soluble components that influence HSCs, including the long-term populating (LT-HSC), short-term populating (ST-HSC), or the more differentiated hematopoietic progenitor cells (HPC), as well as the lymphoid and myeloid lineages, remains an active topic of investigation. However, at least two hematopoietic niches have been described, an osteoblastic (or endosteal) niche, ascribed to osteoblasts residing on bone surfaces, and a vascular niche, ascribed to endothelial cells and subendothelial MSCs or pericytes lining marrow sinusoids. Many have argued that more quiescent LT-HSCs and ST-HSCs are located in the osteoblast niche, while differentiating HPCs are located in the vascular niche for mobilization to the periphery (Lord et al. 1975; Shackney et al. 1975; Gong 1978; Nilsson et al. 2001; Heissig et al. 2002; Arai, F. et al. 2004; Balduino et al. 2005; Jang and Sharkis 2007; Bourke et al. 2009). However, these regions in the marrow are so close in proximity (Arai, F. et al. 2004; Kiel et al. 2005; Lo Celso et al. 2009; Xie et al. 2009), that the osteoblast and vascular niches may be the same, or perhaps interchangeable to some degree. Additionally, recent work has identified other cells involved in hematopoiesis that do not fully comply with these proposed niche regions, such as CXC chemokine ligand (CXCL)-12 expressing reticular cells that are scattered throughout the marrow (Tokoyoda et al. 2004; Sugiyama et al. 2006; Omatsu et al. 2010). Below we will discuss the different cellular, matrix and soluble components within the marrow that have been shown to influence hematopoiesis.

Skeletogenesis and the Hematopoietic Niche 157

additional perivascular cell has also been identified as a HME cell type, the nestinexpressing MSCs (Mendez-Ferrer et al. 2010). These, nestin+ MSCs have been shown to be spatially associate with HSPCs in the marrow and to express several HSPC maintenance genes, e.g. CXCL-12, stem cell factor (SCF)/kit ligand, angiopoietin (Ang)-1, interlukin (IL)- 7, vascular cell adhesion molecule (VCAM)-1, and osteopontin (Mendez-Ferrer et al. 2010). Further, numbers of HSPC were rapidly reduced in the marrow of mice that were selectively depleted of nestin+ MSCs (**Table 1**) (Mendez-Ferrer et al. 2010). These mouse models also revealed a necessity for marrow nestin+ MSCs for homing of transferred HSPCs (Mendez-Ferrer et al. 2010). Together, these data suggest that MSCs and associated daughter cells not only make up the physical structure of the HME, but also provide maintenance and

Reticular cells are of mesodermal origin and are a type of fibroblast cell localized to the intertrabecular region of the marrow near both the osteoblast and vascular niches (Weiss 1976; Rouleau et al. 1990). Recently, a sub-set of marrow reticular cells has been shown to express high levels of CXCL-12 (or stromal derived factor (SDF)-1) and have been termed CXCL-12 abundant reticular (CAR) cells (Tokoyoda et al. 2004; Sugiyama et al. 2006). CXCL-12 is reportedly involved in several aspects of hematopoiesis, including HSPC homing and maintenance, as well as B cell development (Nagasawa et al. 1994; Nagasawa et al. 1996; Ara et al. 2003; Broxmeyer et al. 2005; Jung et al. 2006; Sugiyama et al. 2006). Using CXCL-12/GFP knock-in mice, HSPCs, early lineage B cells and plasma B cells have been shown to spatially associate with CAR cells (Tokoyoda et al. 2004), suggesting CAR cells are a HME cell type. To address the importance of CXCL-12 expressing cells in the HME, Omatsu et al. designed a mouse model with selective ablation of CAR cells (**Table 1**) (Omatsu et al. 2010). These assays showed no change in the osteoblast or vascular niches, but impaired production of SCF and CXCL-12, combined with marked reduction in cycling lymphoid and erythroid progenitors. Further, the HSPC population in these mice was more quiescent, diminished in numbers and expressed myeloid selector genes. Finally, CAR cells can give rise to adipocytes and osteoblasts (Bianco et al. 1988; Balduino et al. 2005; Sipkins et al. 2005; Omatsu et al. 2010). Thus, these data combined with the ectopic bone assays and the nestin+ reticular cell studies discussed above, raise the possibility that the CAR, osteoprogenitor and nestin+ cells are from a similar cell pool, sharing differentiation capabilities and roles in

Within the young marrow there are few adipocytes, however this phenomenon is reversed with aging and after marrow insult, such as post irradiation (Burkhardt et al. 1987; Verma et al. 2002). Although adipocytes have been described as having a positive influence on hematopoiesis via growth factors secretion (Lanotte et al. 1982), other studies have reported that these growth factors are in too low a concentration to influence HSPCs and that adipocytes secrete anti-hematopoietic factors as well (Hotamisligil et al. 1993; Zhang, Y. et al. 1995; Yokota et al. 2000; Corre et al. 2006; Belaid-Choucair et al. 2008; Miharada et al. 2008). Further, an increase in marrow adiposity has been negatively correlated with hematopoiesis in vivo (Touw and Lowenberg 1983; Naveiras et al. 2009). Interestingly,

differentiation signals to HSPCs.

hematopoiteitc support.

**3.1.3 Adipocytes** 

**3.1.2 CXCL-12 abundant reticular cells** 

#### **3.1 Cells of the niche**

Experiments designed to identify the cells of the HME date back over fifty years (Pfeiffer 1948; Tavassoli and Crosby 1968; Tavassoli and Weiss 1971; Meck et al. 1973; Friedenstein et al. 1974; Tavassoli and Khademi 1980; Friedenstein et al. 1982; Patt et al. 1982; Tavassoli 1984; Friedenstein et al. 1987; Gurevitch and Fabian 1993; Kawai et al. 1994; Kuznetsov et al. 1997; Hara et al. 2003; Akintoye et al. 2006; Mankani et al. 2007; Sacchetti et al. 2007; Chan, C.K. et al. 2008; Mankani et al. 2008; Song et al. 2010). In these studies, ectopic bone with a functional HME was generated in host mice using various bone marrow derived osteoprogenitor seed cells. More recently, different osteoprogenitor pools have been isolated that can either generate EO-like bone with active hematopoiesis or compact IO-like bone without an HME (Akintoye et al. 2006; Chan, C.K. et al. 2008). Collectively, these studies have shown that functional HMEs form through the progression of EO with contributions from cartilage, bone, vasculature, and marrow stromal cells. Further, similar conclusions about the necessity of EO-derived components, e.g. cells and matrix molecules, were obtained through analyses of several mouse models with skeleto-hematopoietic defects (**Table 1**), including mice with disrupted collagen X function in the HME (Jacenko et al. 1993; Gress and Jacenko 2000; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010). Discussed below are the data describing which cell type(s), associated matrix and soluble factors are necessary for blood cell development in the marrow, including: multipotent stromal cells (fibroblasts, pericytes, reticular cells, and adipocytes), osteoblasts, chondrocytes, endothelial cells, and cells of hematopoietic origin (hematopoietic stem/progenitor cells (HSPC), osteoclasts and macrophages).

#### **3.1.1 Fibroblasts and perivascular cells**

As early as the 1970's, in vitro studies with marrow stromal adherent colonies showed that this pool of cells is able to support hematopoiesis (Friedenstein et al. 1970; Dexter et al. 1973; Friedenstein et al. 1974; Friedenstein et al. 1976; Dexter et al. 1977). These plastic adherent colonies have been thought to contain mesenchymal progenitor cells, and likely mesodermal progenitor cells as well (Petrini et al. 2009). This would account for recent data indicating that marrow derived progenitor cells generate adipocytes, chondrocytes and osteoblasts, traditional mesenchymal cell types, as well as fibroblasts, smooth muscle cells, endothelial cells, and pericytes/subendothelial cells (Bentley and Foidart 1980; Muguruma et al. 2006; Sacchetti et al. 2007; Crisan et al. 2008; Kalajzic et al. 2008; Augello et al. 2010; Mendez-Ferrer et al. 2010). Thus, isolated marrow stromal cells will be referred to as multipotent stromal cells (MSC) throughout (Horwitz et al. 2005). The MSCs isolated for ectopic bone assays have been described as osteoprogenitor cells that generate bone with a HME able to support host-derived hematopoiesis (Kuznetsov et al. 1997; Akintoye et al. 2006; Sacchetti et al. 2007; Chan, C.K. et al. 2008; Morikawa et al. 2009). Of note, many of these osteoprogenitor cells have been shown to have stem-like qualities, such as self-replication and the ability to differentiate into several different cell types. For example, Sacchetti et al. isolated humanderived MCAM/CD146-expressing subendothelial cells, which can self-replicate as well as give rise to osteoblasts, chondrocytes and reticular cells in ectopic HMEs (Sacchetti et al. 2007). More recently, these data were replicated in the mouse by Morikawa et al. who also identified a perivascular cell type that has the ability to self-replicate and give rise to adipocytes, osteoblasts, chondrocytes and endothelial cells (Morikawa et al. 2009). An

Experiments designed to identify the cells of the HME date back over fifty years (Pfeiffer 1948; Tavassoli and Crosby 1968; Tavassoli and Weiss 1971; Meck et al. 1973; Friedenstein et al. 1974; Tavassoli and Khademi 1980; Friedenstein et al. 1982; Patt et al. 1982; Tavassoli 1984; Friedenstein et al. 1987; Gurevitch and Fabian 1993; Kawai et al. 1994; Kuznetsov et al. 1997; Hara et al. 2003; Akintoye et al. 2006; Mankani et al. 2007; Sacchetti et al. 2007; Chan, C.K. et al. 2008; Mankani et al. 2008; Song et al. 2010). In these studies, ectopic bone with a functional HME was generated in host mice using various bone marrow derived osteoprogenitor seed cells. More recently, different osteoprogenitor pools have been isolated that can either generate EO-like bone with active hematopoiesis or compact IO-like bone without an HME (Akintoye et al. 2006; Chan, C.K. et al. 2008). Collectively, these studies have shown that functional HMEs form through the progression of EO with contributions from cartilage, bone, vasculature, and marrow stromal cells. Further, similar conclusions about the necessity of EO-derived components, e.g. cells and matrix molecules, were obtained through analyses of several mouse models with skeleto-hematopoietic defects (**Table 1**), including mice with disrupted collagen X function in the HME (Jacenko et al. 1993; Gress and Jacenko 2000; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010). Discussed below are the data describing which cell type(s), associated matrix and soluble factors are necessary for blood cell development in the marrow, including: multipotent stromal cells (fibroblasts, pericytes, reticular cells, and adipocytes), osteoblasts, chondrocytes, endothelial cells, and cells of hematopoietic origin (hematopoietic

As early as the 1970's, in vitro studies with marrow stromal adherent colonies showed that this pool of cells is able to support hematopoiesis (Friedenstein et al. 1970; Dexter et al. 1973; Friedenstein et al. 1974; Friedenstein et al. 1976; Dexter et al. 1977). These plastic adherent colonies have been thought to contain mesenchymal progenitor cells, and likely mesodermal progenitor cells as well (Petrini et al. 2009). This would account for recent data indicating that marrow derived progenitor cells generate adipocytes, chondrocytes and osteoblasts, traditional mesenchymal cell types, as well as fibroblasts, smooth muscle cells, endothelial cells, and pericytes/subendothelial cells (Bentley and Foidart 1980; Muguruma et al. 2006; Sacchetti et al. 2007; Crisan et al. 2008; Kalajzic et al. 2008; Augello et al. 2010; Mendez-Ferrer et al. 2010). Thus, isolated marrow stromal cells will be referred to as multipotent stromal cells (MSC) throughout (Horwitz et al. 2005). The MSCs isolated for ectopic bone assays have been described as osteoprogenitor cells that generate bone with a HME able to support host-derived hematopoiesis (Kuznetsov et al. 1997; Akintoye et al. 2006; Sacchetti et al. 2007; Chan, C.K. et al. 2008; Morikawa et al. 2009). Of note, many of these osteoprogenitor cells have been shown to have stem-like qualities, such as self-replication and the ability to differentiate into several different cell types. For example, Sacchetti et al. isolated humanderived MCAM/CD146-expressing subendothelial cells, which can self-replicate as well as give rise to osteoblasts, chondrocytes and reticular cells in ectopic HMEs (Sacchetti et al. 2007). More recently, these data were replicated in the mouse by Morikawa et al. who also identified a perivascular cell type that has the ability to self-replicate and give rise to adipocytes, osteoblasts, chondrocytes and endothelial cells (Morikawa et al. 2009). An

stem/progenitor cells (HSPC), osteoclasts and macrophages).

**3.1.1 Fibroblasts and perivascular cells** 

**3.1 Cells of the niche** 

additional perivascular cell has also been identified as a HME cell type, the nestinexpressing MSCs (Mendez-Ferrer et al. 2010). These, nestin+ MSCs have been shown to be spatially associate with HSPCs in the marrow and to express several HSPC maintenance genes, e.g. CXCL-12, stem cell factor (SCF)/kit ligand, angiopoietin (Ang)-1, interlukin (IL)- 7, vascular cell adhesion molecule (VCAM)-1, and osteopontin (Mendez-Ferrer et al. 2010). Further, numbers of HSPC were rapidly reduced in the marrow of mice that were selectively depleted of nestin+ MSCs (**Table 1**) (Mendez-Ferrer et al. 2010). These mouse models also revealed a necessity for marrow nestin+ MSCs for homing of transferred HSPCs (Mendez-Ferrer et al. 2010). Together, these data suggest that MSCs and associated daughter cells not only make up the physical structure of the HME, but also provide maintenance and differentiation signals to HSPCs.

#### **3.1.2 CXCL-12 abundant reticular cells**

Reticular cells are of mesodermal origin and are a type of fibroblast cell localized to the intertrabecular region of the marrow near both the osteoblast and vascular niches (Weiss 1976; Rouleau et al. 1990). Recently, a sub-set of marrow reticular cells has been shown to express high levels of CXCL-12 (or stromal derived factor (SDF)-1) and have been termed CXCL-12 abundant reticular (CAR) cells (Tokoyoda et al. 2004; Sugiyama et al. 2006). CXCL-12 is reportedly involved in several aspects of hematopoiesis, including HSPC homing and maintenance, as well as B cell development (Nagasawa et al. 1994; Nagasawa et al. 1996; Ara et al. 2003; Broxmeyer et al. 2005; Jung et al. 2006; Sugiyama et al. 2006). Using CXCL-12/GFP knock-in mice, HSPCs, early lineage B cells and plasma B cells have been shown to spatially associate with CAR cells (Tokoyoda et al. 2004), suggesting CAR cells are a HME cell type. To address the importance of CXCL-12 expressing cells in the HME, Omatsu et al. designed a mouse model with selective ablation of CAR cells (**Table 1**) (Omatsu et al. 2010). These assays showed no change in the osteoblast or vascular niches, but impaired production of SCF and CXCL-12, combined with marked reduction in cycling lymphoid and erythroid progenitors. Further, the HSPC population in these mice was more quiescent, diminished in numbers and expressed myeloid selector genes. Finally, CAR cells can give rise to adipocytes and osteoblasts (Bianco et al. 1988; Balduino et al. 2005; Sipkins et al. 2005; Omatsu et al. 2010). Thus, these data combined with the ectopic bone assays and the nestin+ reticular cell studies discussed above, raise the possibility that the CAR, osteoprogenitor and nestin+ cells are from a similar cell pool, sharing differentiation capabilities and roles in hematopoiteitc support.

#### **3.1.3 Adipocytes**

Within the young marrow there are few adipocytes, however this phenomenon is reversed with aging and after marrow insult, such as post irradiation (Burkhardt et al. 1987; Verma et al. 2002). Although adipocytes have been described as having a positive influence on hematopoiesis via growth factors secretion (Lanotte et al. 1982), other studies have reported that these growth factors are in too low a concentration to influence HSPCs and that adipocytes secrete anti-hematopoietic factors as well (Hotamisligil et al. 1993; Zhang, Y. et al. 1995; Yokota et al. 2000; Corre et al. 2006; Belaid-Choucair et al. 2008; Miharada et al. 2008). Further, an increase in marrow adiposity has been negatively correlated with hematopoiesis in vivo (Touw and Lowenberg 1983; Naveiras et al. 2009). Interestingly,

Skeletogenesis and the Hematopoietic Niche 159

al. 2009). For instance, Xie et al. showed that GFP+ HSPCs home to the trabecular bone surface in the marrow, and others have reported early developing B lymphocytes at the endosteal region of the marrow (Hermans et al. 1989; Jacobsen and Osmond 1990; Osmond 1990; Xie et al. 2009). This zone is the chondro-osseous region where hypertrophic chondrocytes, trabecular osteoblasts and marrow cells are juxtaposed (**Fig. 1**). Hypertrophic chondrocytes and their matrix components are also essential for trabecular bone formation, and are proposed to be part of the osteoblast/lymphopoietic niche (Jacenko et al. 2002; Rodgers et al. 2008; Sweeney et al. 2008; Sweeney et al. 2010). Interestingly, hypertrophic chondrocytes have been described to trans-differentiate into osteoblasts (Roach 1992; Galotto et al. 1994; Roach et al. 1995; Roach and Erenpreisa 1996), and express osteoblast-like markers, e.g. osterix, osteocalcin, osteonectin, osteopontin and collagen I (Roach 1992; Yagi et al. 2003), suggesting similarities in the cells of the chondro-osseous niche. Indeed, it has been suggested that chondro-osteoprogenitor cells that expresses the chondrocyte-like marker collagen II contribute to both the perichondrial and trabecular osteoblast populations (Nakamura et al. 2006; Hilton et al. 2007). In contrast, however Maes et al. do not report any contribution from the collagen II labeled hypertrophic chondrocytes to trabecular bone (Maes et al. 2010). Taken together, these finding are reminiscent of the reports indicating that progenitor cells in the marrow can give rise to different cell types with many similarities, e.g. osteoprogenitors, CAR and nestin+ cells not only share gene expression profiles, but are all located in the chondro-osseous environment (Weiss 1976; Rouleau et al. 1990; Sugiyama et al. 2006). The possible overlap between the cells of the chondro-osseous region can also be appreciated when comparing osteoblasts and reticular cells that can support B lymphopoiesis and both express VCAM-1 and IL-7 (Ryan et al. 1991; Funk et al. 1995; Zhu et al. 2007). Moreover, using an osteoblast lineage tracer mouse generated with an osterix-LacZ construct, cells of the perichondrium, trabecular bone, cartilage and marrow stroma, some intimately associated with blood vessels in a pericytelike fashion, were all positive for osterix expression (Maes et al. 2010), again confirming an

As previously discussed, chondrocytes provide the blueprint for future bone with a marrow cavity during EO, and are adjacent to the postulated osteoblast and vascular niches (**Fig. 1B boxed**) (Arai, F. et al. 2004; Kiel et al. 2005; Kohler et al. 2009; Xie et al. 2009). Indeed, growth plate chondrocytes, as well as osteoblasts and vascular cells, express leukemia inhibitory factor (LIF), which can synergize with growth factors to promote the proliferation of HSPCs (Keller et al. 1996; Grimaud et al. 2002). Additionally, Wei et al. recently showed that hypertrophic chondrocytes express CXCR-4, the receptor for CXCL-12 made by stromal cells and osteoblasts (Peled et al. 1999; Kortesidis et al. 2005; Dar et al. 2006; Jung et al. 2006; Sacchetti et al. 2007; Wei et al. 2010). These data begin to reveal the cross talk between the hypertrophic chondrocytes and the cells of the chondro-osseous environment that are players within the hematopoietic niche, e.g. osteoblasts, stromal and hematopoietic cells.

To date, no imaging studies have attempted to localize HSPCs to hypertrophic chondrocytes. However, the contribution of various matrix components, in particular the heparan sulfate proteoglycans (HSPG), in establishing reservoirs of soluble factors for cell signaling and/or retention of HSPCs has been well established (as reviewed in (Rodgers et

overlap of cell phenotypes in the chondro-osseous HME.

**3.1.5 Chondrocytes** 

Naveiras et al. have shown that in the adult mouse spine there is a proximal to distal gradient of marrow adipocity, with thoracic vertebrae being virtually free of adipocytes. This provides an in vivo model to study the affects of adipocytes on hematopoietic cells under homeostatic conditions. These studies showed that the number, frequency and cycling capacity of HSPCs was reduced as the number of adipocytes was increased (Naveiras et al. 2009). In support, after irradiation and marrow transplantation of mice genetically incapable of forming adipocytes, or in wild type mice treated with an inhibitor of adipogenesis, there was enhanced HSPC expansion compared to non-treated wild type cohorts (Naveiras et al. 2009). Of note, in these models of reduced/abrogated adipogenesis, as well as in a model where the fatty marrow is surgically removed, the increase in hematopoiesis is concomitant with an increase in bone formation (Tavassoli et al. 1974; Naveiras et al. 2009). These data suggest that after marrow insult and in the absence of adipocytes, there are signals enhancing osteoblast activity and bone formation, which may contribute to the enhanced hematopoiesis measured, as discussed below. This is supported by the clinical observations that aged patients have an increase in adiposity in the marrow, which is correlated with a decrease in bone formation and decreased hematopoiesis (Verma et al. 2002; Rossi et al. 2005; Mayack et al. 2010).

#### **3.1.4 Osteoblasts**

With the identification of osteoblast-like cells in stromal cultures (Friedenstein et al. 1987; Benayahu et al. 1991; Benayahu et al. 1992) and osteoprogenitors within marrow preparations for ectopic bone assays (Kuznetsov et al. 1997; Akintoye et al. 2006; Sacchetti et al. 2007; Chan, C.K. et al. 2008; Morikawa et al. 2009), Emerson and Taichman designed in vitro assays to assess the ability of isolated osteoblasts to support hematopoiesis (Taichman and Emerson 1994; Taichman et al. 1996; Taichman et al. 1997; Jung et al. 2005; Jung et al. 2006; Zhu et al. 2007). These assays showed that osteoblasts can support hematopoiesis through the secretion of pro-hematopoietic cytokines, e.g. granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), CXCL-12, IL-6, and IL-7, and that cell-cell contact is necessary for support via integrin binding (very late antigen (VLA)-4/5 and VCAM/ICAM). Further, these assays confirmed a connection between osteoblasts and B cell development. To assess the contribution of osteoblasts to hematopoiesis in vivo, several different mouse models have been generated that either increase osteoblasts (Calvi et al. 2001; Calvi et al. 2003; Zhang, J. et al. 2003), decrease osteoblasts (Visnjic et al. 2001; Visnjic et al. 2004), disrupt EO-based trabecular bone formation (Jacenko et al. 1993; Gress and Jacenko 2000; Jacenko et al. 2001; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010), alter osteoblast signaling (Wu et al. 2008), or modify osteoblast RNA processing (**Table 1**) (Raaijmakers et al. 2010). These in vivo models have confirmed that osteoblasts can support hematopoiesis, are involved in B lymphopoiesis, make pro-hematopoietic cytokines, make cell-cell contact with HSPCs, and moreover, have implicated osterix expressing osteoprogenitors as mediators of hematopoiesis.

The above studies, as well as many imaging studies of HSPC in bone, support the osteoblast hematopoietic niche theory and suggest that the osteoblast niche may additionally encompass the B lymphopoietic niche (Nilsson et al. 1997; Nilsson et al. 2001; Yoshimoto et al. 2003; Arai, F. et al. 2004; Balduino et al. 2005; Kohler et al. 2009; Lo Celso et al. 2009; Xie et

Naveiras et al. have shown that in the adult mouse spine there is a proximal to distal gradient of marrow adipocity, with thoracic vertebrae being virtually free of adipocytes. This provides an in vivo model to study the affects of adipocytes on hematopoietic cells under homeostatic conditions. These studies showed that the number, frequency and cycling capacity of HSPCs was reduced as the number of adipocytes was increased (Naveiras et al. 2009). In support, after irradiation and marrow transplantation of mice genetically incapable of forming adipocytes, or in wild type mice treated with an inhibitor of adipogenesis, there was enhanced HSPC expansion compared to non-treated wild type cohorts (Naveiras et al. 2009). Of note, in these models of reduced/abrogated adipogenesis, as well as in a model where the fatty marrow is surgically removed, the increase in hematopoiesis is concomitant with an increase in bone formation (Tavassoli et al. 1974; Naveiras et al. 2009). These data suggest that after marrow insult and in the absence of adipocytes, there are signals enhancing osteoblast activity and bone formation, which may contribute to the enhanced hematopoiesis measured, as discussed below. This is supported by the clinical observations that aged patients have an increase in adiposity in the marrow, which is correlated with a decrease in bone formation and decreased hematopoiesis (Verma

With the identification of osteoblast-like cells in stromal cultures (Friedenstein et al. 1987; Benayahu et al. 1991; Benayahu et al. 1992) and osteoprogenitors within marrow preparations for ectopic bone assays (Kuznetsov et al. 1997; Akintoye et al. 2006; Sacchetti et al. 2007; Chan, C.K. et al. 2008; Morikawa et al. 2009), Emerson and Taichman designed in vitro assays to assess the ability of isolated osteoblasts to support hematopoiesis (Taichman and Emerson 1994; Taichman et al. 1996; Taichman et al. 1997; Jung et al. 2005; Jung et al. 2006; Zhu et al. 2007). These assays showed that osteoblasts can support hematopoiesis through the secretion of pro-hematopoietic cytokines, e.g. granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), CXCL-12, IL-6, and IL-7, and that cell-cell contact is necessary for support via integrin binding (very late antigen (VLA)-4/5 and VCAM/ICAM). Further, these assays confirmed a connection between osteoblasts and B cell development. To assess the contribution of osteoblasts to hematopoiesis in vivo, several different mouse models have been generated that either increase osteoblasts (Calvi et al. 2001; Calvi et al. 2003; Zhang, J. et al. 2003), decrease osteoblasts (Visnjic et al. 2001; Visnjic et al. 2004), disrupt EO-based trabecular bone formation (Jacenko et al. 1993; Gress and Jacenko 2000; Jacenko et al. 2001; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010), alter osteoblast signaling (Wu et al. 2008), or modify osteoblast RNA processing (**Table 1**) (Raaijmakers et al. 2010). These in vivo models have confirmed that osteoblasts can support hematopoiesis, are involved in B lymphopoiesis, make pro-hematopoietic cytokines, make cell-cell contact with HSPCs, and moreover, have implicated osterix expressing osteoprogenitors as mediators of

The above studies, as well as many imaging studies of HSPC in bone, support the osteoblast hematopoietic niche theory and suggest that the osteoblast niche may additionally encompass the B lymphopoietic niche (Nilsson et al. 1997; Nilsson et al. 2001; Yoshimoto et al. 2003; Arai, F. et al. 2004; Balduino et al. 2005; Kohler et al. 2009; Lo Celso et al. 2009; Xie et

et al. 2002; Rossi et al. 2005; Mayack et al. 2010).

**3.1.4 Osteoblasts** 

hematopoiesis.

al. 2009). For instance, Xie et al. showed that GFP+ HSPCs home to the trabecular bone surface in the marrow, and others have reported early developing B lymphocytes at the endosteal region of the marrow (Hermans et al. 1989; Jacobsen and Osmond 1990; Osmond 1990; Xie et al. 2009). This zone is the chondro-osseous region where hypertrophic chondrocytes, trabecular osteoblasts and marrow cells are juxtaposed (**Fig. 1**). Hypertrophic chondrocytes and their matrix components are also essential for trabecular bone formation, and are proposed to be part of the osteoblast/lymphopoietic niche (Jacenko et al. 2002; Rodgers et al. 2008; Sweeney et al. 2008; Sweeney et al. 2010). Interestingly, hypertrophic chondrocytes have been described to trans-differentiate into osteoblasts (Roach 1992; Galotto et al. 1994; Roach et al. 1995; Roach and Erenpreisa 1996), and express osteoblast-like markers, e.g. osterix, osteocalcin, osteonectin, osteopontin and collagen I (Roach 1992; Yagi et al. 2003), suggesting similarities in the cells of the chondro-osseous niche. Indeed, it has been suggested that chondro-osteoprogenitor cells that expresses the chondrocyte-like marker collagen II contribute to both the perichondrial and trabecular osteoblast populations (Nakamura et al. 2006; Hilton et al. 2007). In contrast, however Maes et al. do not report any contribution from the collagen II labeled hypertrophic chondrocytes to trabecular bone (Maes et al. 2010). Taken together, these finding are reminiscent of the reports indicating that progenitor cells in the marrow can give rise to different cell types with many similarities, e.g. osteoprogenitors, CAR and nestin+ cells not only share gene expression profiles, but are all located in the chondro-osseous environment (Weiss 1976; Rouleau et al. 1990; Sugiyama et al. 2006). The possible overlap between the cells of the chondro-osseous region can also be appreciated when comparing osteoblasts and reticular cells that can support B lymphopoiesis and both express VCAM-1 and IL-7 (Ryan et al. 1991; Funk et al. 1995; Zhu et al. 2007). Moreover, using an osteoblast lineage tracer mouse generated with an osterix-LacZ construct, cells of the perichondrium, trabecular bone, cartilage and marrow stroma, some intimately associated with blood vessels in a pericytelike fashion, were all positive for osterix expression (Maes et al. 2010), again confirming an overlap of cell phenotypes in the chondro-osseous HME.

#### **3.1.5 Chondrocytes**

As previously discussed, chondrocytes provide the blueprint for future bone with a marrow cavity during EO, and are adjacent to the postulated osteoblast and vascular niches (**Fig. 1B boxed**) (Arai, F. et al. 2004; Kiel et al. 2005; Kohler et al. 2009; Xie et al. 2009). Indeed, growth plate chondrocytes, as well as osteoblasts and vascular cells, express leukemia inhibitory factor (LIF), which can synergize with growth factors to promote the proliferation of HSPCs (Keller et al. 1996; Grimaud et al. 2002). Additionally, Wei et al. recently showed that hypertrophic chondrocytes express CXCR-4, the receptor for CXCL-12 made by stromal cells and osteoblasts (Peled et al. 1999; Kortesidis et al. 2005; Dar et al. 2006; Jung et al. 2006; Sacchetti et al. 2007; Wei et al. 2010). These data begin to reveal the cross talk between the hypertrophic chondrocytes and the cells of the chondro-osseous environment that are players within the hematopoietic niche, e.g. osteoblasts, stromal and hematopoietic cells.

To date, no imaging studies have attempted to localize HSPCs to hypertrophic chondrocytes. However, the contribution of various matrix components, in particular the heparan sulfate proteoglycans (HSPG), in establishing reservoirs of soluble factors for cell signaling and/or retention of HSPCs has been well established (as reviewed in (Rodgers et

Skeletogenesis and the Hematopoietic Niche 161

hematopoiesis takes place in the yolk sac, aorta-gonad-mesonephros region and placenta perivascularly (Cumano et al. 1996; Medvinsky and Dzierzak 1996; Sanchez et al. 1996; de Bruijn et al. 2002; North et al. 2002; Gekas et al. 2005; Ottersbach and Dzierzak 2005). Additionally, throughout life in some species, such as the zebra fish, hematopoiesis is not coincident with bone (Murayama et al. 2006). Further, the characteristics of the marrow sinusoids, e.g. chemokine and adhesion molecule expression, not only allow them to be conduits for hematopoietic cells to and from the circulation, but also to serve as an area for HSPC differentiation (Rafii et al. 1994; Rafii et al. 1995; Schweitzer et al. 1996; Naiyer et al. 1999; Abkowitz et al. 2003; Avecilla et al. 2004). In agreement, endothelial cells from several sources are able to support HSPC maintenance and differentiation toward lymphoid and myeloid lineages in culture (Rafii et al. 1995; Ohneda et al. 1998; Li et al. 2004; Wittig et al. 2009; Butler et al. 2010). Visualizing the vascular niche in vivo with a pure sub-set of HSCs also provided support for the vascular niche theory. These studies revealed approximately 60% of HSC residing in the chondro-osseous HME, and of that population, approximately 60% were proximal to the vasculature, where as 15% were near bone (Kiel et al. 2005). Moreover, one aspect of the osteoblast niche theory maintains that HSCs are bound to osteoblasts by a N-cadherin-mediated homophilic adhesion, however in a mouse model where HSC specific N-cadherin was depleted, hematopoiesis was fully functional (Zhang, J. et al. 2003; Kiel et al. 2009). More in vivo support is provided by the biglycan deficient mice, which present with decreased trabecular osteoblasts and bone formation, however show no defects in hematopoiesis, HSC frequency or function, and show HSC localization to the vasculature (Kiel et al. 2007). These data suggest an overlap in niche location with perhaps some ability for compensation between the osteoblast and vascular niches, albeit limited. In support, via histochemistry of the long bone, one can appreciate the spatial proximity of

Discussed above are the data linking non-hematopoietic cells with hematopoiesis, however there are also data supporting reciprocal affects of hematopoietic derived cells influencing non-hematopoietic lineages. For example, HSPCs regulate MSC differentiation toward the osteoblast lineage via expression of BMP-2 and -6, suggesting that the HSPCs can actively maintain the osteoblast niche (Jung et al. 2008). Additionally, macrophages intercalated throughout bone have been described as osteoblast helper cells since they promote osteoblast mineralization in vitro and form a canopy over osteoblasts generating bone in vivo (Chang et al. 2008). An additional player in osteoblastogenesis is the megakaryocyte. In mouse models with increased numbers of megakaryocytes due to maturation arrest, increased osteoblast proliferation and bone mass were measured (Kacena et al. 2004). Additionally, megakaryocytes have been described as niche restoring cells post-irradiation since they migrate to the damaged bone surfaces and increase local concentrations of CXCL-12, platelet-derived growth factor (PDGF)- and basic fibroblast growth factor (bFGF), which are associated with osteoblast proliferation (Kacena et al. 2006; Dominici et al. 2009). A reciprocal balance between bone deposition by osteoblasts, bone resorption by osteoclasts and signaling by osteocytes is extensively noted in the literature, and is appreciated clinically. These coupled interactions will not be discussed here other than to acknowledge

osteoblasts to the vasculature (**Fig. 1B boxed**).

**3.1.7 Hematopoietic derived cells influence the niche** 

al. 2008) also see (Gordon et al. 1988; Roberts et al. 1988; Siczkowski et al. 1992; Verfaillie 1993; Allouche and Bikfalvi 1995; Bruno et al. 1995; Klein et al. 1995; Gupta et al. 1996; Gupta et al. 1998; Borghesi et al. 1999; Siebertz et al. 1999; Zweegman et al. 2004; Rodgers et al. 2008; Spiegel et al. 2008). In support, our laboratory has shown altered localization of both hyaluronan and HSPGs within the hypertrophic cartilage zone of the growth plates in the collagen X mouse models that display altered hematopoiesis (Jacenko et al. 2001), which directly links EO and the hypertrophic cartilage matrix to hematopoiesis (Jacenko et al. 1993; Gress and Jacenko 2000; Jacenko et al. 2001; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010). Briefly, collagen X is a short chain, network forming collagen that is the major secreted matrix protein of hypertrophic chondrocytes and is localized to the hypertrophic cartilage/chondro-osseous region (Campbell et al. 2004), where it is proposed to form a hexagonal lattice-like network in the matrix (Jacenko et al. 1991; Chan, D. and Jacenko 1998). Affinity co-electrophoresis studies demonstrated that collagen X and heparin, a structural analog of heparan sulfate, can endogenously bind (Sweeney, unpublished). We thus proposed that the hypertrophic chondrocyte derived matrix, made up of the collagen X network that is likely stabilized by associating with the HSPGs, is enriched with hematopoietic factors and is a vital component of the HME (Jacenko et al. 2001; Rodgers et al. 2008). In accord, mouse models where the function of collagen X was altered via transgenesis or targeted gene knock-out have both an altered HME structure, as well as aberrant hematopoiesis. Specifically, alterations within the EO-derived chondro-osseous junction include aberrant growth plate histomorphometry, collapsed hypertrophic chondrocyte matrix network, diminished and altered localization for HSPG within hypertrophic cartilage and trabecular bone, and decreased trabecular bone. The hematopoietic changes include diminished B lymphopoiesis throughout life, perinatal lethality within a sub-set of mice due to opportunistic infections by the third week of life, decreased responses to concanavalin A by splenocytes from mice at all ages, and the succumbing of all collagen X mice to non-virulent pathogen challenge (**Table 1**) (Jacenko et al. 1993; Rosati et al. 1994; Jacenko et al. 1996; Kwan et al. 1997; Gress and Jacenko 2000; Jacenko et al. 2001; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010). Additionally, altered levels of hematopoietic cytokines have been measured from the collagen X mouse derived hypertrophic chondrocytes and trabecular osteoblasts when compared to wild type cohorts (Sweeney, 2011 Ann N Y Acad. Sci. in press). The altered cytokine availability may negatively affect hematopoiesis, which may be even further amplified by the altered chondro-osseous matrix in the collagen X mice, e.g. loss of functional collagen X and diminished HSPGs at the chondro-ossous HME (Jacenko et al. 2001). In support of the notion that matrix/cytokine signaling can affect cell differentiation in the HME, fate switching was sited as the cause of decreased osteoblast progenitors and bone formation in a knock-out mouse for the critical transforming growth factor (TGF) binding proteoglycans, biglycan and decorin (Bi et al. 2005). Overall, the collagen X mouse models have highlighted the contribution of EO-derived cells and matrix components to HMEs and to hematopoietic cell development.

#### **3.1.6 Endothelial cells**

Marrow arterioles and capillaries supply the sinusoids, which in turn supply the marrow with cells and nutrients (reviewed in (Kopp et al. 2005). These are the sites of the vascular niche, and examples of active vascular niches can be appreciated during development when

al. 2008) also see (Gordon et al. 1988; Roberts et al. 1988; Siczkowski et al. 1992; Verfaillie 1993; Allouche and Bikfalvi 1995; Bruno et al. 1995; Klein et al. 1995; Gupta et al. 1996; Gupta et al. 1998; Borghesi et al. 1999; Siebertz et al. 1999; Zweegman et al. 2004; Rodgers et al. 2008; Spiegel et al. 2008). In support, our laboratory has shown altered localization of both hyaluronan and HSPGs within the hypertrophic cartilage zone of the growth plates in the collagen X mouse models that display altered hematopoiesis (Jacenko et al. 2001), which directly links EO and the hypertrophic cartilage matrix to hematopoiesis (Jacenko et al. 1993; Gress and Jacenko 2000; Jacenko et al. 2001; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010). Briefly, collagen X is a short chain, network forming collagen that is the major secreted matrix protein of hypertrophic chondrocytes and is localized to the hypertrophic cartilage/chondro-osseous region (Campbell et al. 2004), where it is proposed to form a hexagonal lattice-like network in the matrix (Jacenko et al. 1991; Chan, D. and Jacenko 1998). Affinity co-electrophoresis studies demonstrated that collagen X and heparin, a structural analog of heparan sulfate, can endogenously bind (Sweeney, unpublished). We thus proposed that the hypertrophic chondrocyte derived matrix, made up of the collagen X network that is likely stabilized by associating with the HSPGs, is enriched with hematopoietic factors and is a vital component of the HME (Jacenko et al. 2001; Rodgers et al. 2008). In accord, mouse models where the function of collagen X was altered via transgenesis or targeted gene knock-out have both an altered HME structure, as well as aberrant hematopoiesis. Specifically, alterations within the EO-derived chondro-osseous junction include aberrant growth plate histomorphometry, collapsed hypertrophic chondrocyte matrix network, diminished and altered localization for HSPG within hypertrophic cartilage and trabecular bone, and decreased trabecular bone. The hematopoietic changes include diminished B lymphopoiesis throughout life, perinatal lethality within a sub-set of mice due to opportunistic infections by the third week of life, decreased responses to concanavalin A by splenocytes from mice at all ages, and the succumbing of all collagen X mice to non-virulent pathogen challenge (**Table 1**) (Jacenko et al. 1993; Rosati et al. 1994; Jacenko et al. 1996; Kwan et al. 1997; Gress and Jacenko 2000; Jacenko et al. 2001; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010). Additionally, altered levels of hematopoietic cytokines have been measured from the collagen X mouse derived hypertrophic chondrocytes and trabecular osteoblasts when compared to wild type cohorts (Sweeney, 2011 Ann N Y Acad. Sci. in press). The altered cytokine availability may negatively affect hematopoiesis, which may be even further amplified by the altered chondro-osseous matrix in the collagen X mice, e.g. loss of functional collagen X and diminished HSPGs at the chondro-ossous HME (Jacenko et al. 2001). In support of the notion that matrix/cytokine signaling can affect cell differentiation in the HME, fate switching was sited as the cause of decreased osteoblast progenitors and bone formation in a knock-out mouse for the critical transforming growth factor (TGF) binding proteoglycans, biglycan and decorin (Bi et al. 2005). Overall, the collagen X mouse models have highlighted the contribution of EO-derived cells and matrix components to

Marrow arterioles and capillaries supply the sinusoids, which in turn supply the marrow with cells and nutrients (reviewed in (Kopp et al. 2005). These are the sites of the vascular niche, and examples of active vascular niches can be appreciated during development when

HMEs and to hematopoietic cell development.

**3.1.6 Endothelial cells** 

hematopoiesis takes place in the yolk sac, aorta-gonad-mesonephros region and placenta perivascularly (Cumano et al. 1996; Medvinsky and Dzierzak 1996; Sanchez et al. 1996; de Bruijn et al. 2002; North et al. 2002; Gekas et al. 2005; Ottersbach and Dzierzak 2005). Additionally, throughout life in some species, such as the zebra fish, hematopoiesis is not coincident with bone (Murayama et al. 2006). Further, the characteristics of the marrow sinusoids, e.g. chemokine and adhesion molecule expression, not only allow them to be conduits for hematopoietic cells to and from the circulation, but also to serve as an area for HSPC differentiation (Rafii et al. 1994; Rafii et al. 1995; Schweitzer et al. 1996; Naiyer et al. 1999; Abkowitz et al. 2003; Avecilla et al. 2004). In agreement, endothelial cells from several sources are able to support HSPC maintenance and differentiation toward lymphoid and myeloid lineages in culture (Rafii et al. 1995; Ohneda et al. 1998; Li et al. 2004; Wittig et al. 2009; Butler et al. 2010). Visualizing the vascular niche in vivo with a pure sub-set of HSCs also provided support for the vascular niche theory. These studies revealed approximately 60% of HSC residing in the chondro-osseous HME, and of that population, approximately 60% were proximal to the vasculature, where as 15% were near bone (Kiel et al. 2005). Moreover, one aspect of the osteoblast niche theory maintains that HSCs are bound to osteoblasts by a N-cadherin-mediated homophilic adhesion, however in a mouse model where HSC specific N-cadherin was depleted, hematopoiesis was fully functional (Zhang, J. et al. 2003; Kiel et al. 2009). More in vivo support is provided by the biglycan deficient mice, which present with decreased trabecular osteoblasts and bone formation, however show no defects in hematopoiesis, HSC frequency or function, and show HSC localization to the vasculature (Kiel et al. 2007). These data suggest an overlap in niche location with perhaps some ability for compensation between the osteoblast and vascular niches, albeit limited. In support, via histochemistry of the long bone, one can appreciate the spatial proximity of osteoblasts to the vasculature (**Fig. 1B boxed**).

#### **3.1.7 Hematopoietic derived cells influence the niche**

Discussed above are the data linking non-hematopoietic cells with hematopoiesis, however there are also data supporting reciprocal affects of hematopoietic derived cells influencing non-hematopoietic lineages. For example, HSPCs regulate MSC differentiation toward the osteoblast lineage via expression of BMP-2 and -6, suggesting that the HSPCs can actively maintain the osteoblast niche (Jung et al. 2008). Additionally, macrophages intercalated throughout bone have been described as osteoblast helper cells since they promote osteoblast mineralization in vitro and form a canopy over osteoblasts generating bone in vivo (Chang et al. 2008). An additional player in osteoblastogenesis is the megakaryocyte. In mouse models with increased numbers of megakaryocytes due to maturation arrest, increased osteoblast proliferation and bone mass were measured (Kacena et al. 2004). Additionally, megakaryocytes have been described as niche restoring cells post-irradiation since they migrate to the damaged bone surfaces and increase local concentrations of CXCL-12, platelet-derived growth factor (PDGF)- and basic fibroblast growth factor (bFGF), which are associated with osteoblast proliferation (Kacena et al. 2006; Dominici et al. 2009).

A reciprocal balance between bone deposition by osteoblasts, bone resorption by osteoclasts and signaling by osteocytes is extensively noted in the literature, and is appreciated clinically. These coupled interactions will not be discussed here other than to acknowledge

Skeletogenesis and the Hematopoietic Niche 163

 relevant to the collagen X mouse models that present with a disrupted collagen X network coupled with a decreased HSPG staining intensity at the chondro-osseous HME and diminished cytokine levels, leading to diminished B lymphopoiesis (Gress and Jacenko 2000; Jacenko et al. 2001; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010). These findings imply that the structural defects in the matrix may lead to changes in the cytokine reservoirs, which in turn would negatively affect hematopoietic cell development. By extension, human diseases associated with altered matrix components at the HME may have altered hematopoiesis due to changes in cytokine availability, such as with Simpson-Golabi Behmel syndrome where alterations in the HSPG glypican-3 results in skeletal and

There is increasing evidence that the nervous system can also affect the immune system through neurotransmitter signaling. The bone and marrow are supplied with autonomic efferent and afferent sensory innervations, specifically at the epiphysis and metaphysis of long bone, which includes the chondro-osseous HME (**Fig. 1A**) (reviewed in (Mignini et al. 2003). Catecholamines, acetylcholine and peptide transmitters of neural and non-neural origin are released in the HME, which contribute to neuro-immune modulations. For example, signaling from the nervous system can regulate HSPC egress and repopulation of the marrow (Katayama et al. 2006; Spiegel et al. 2007), which has been shown to be coupled to the circadian rhythm (Mendez-Ferrer et al. 2008). Indeed, HSPCs have receptors for several neurotransmitters, which can stimulate cell proliferation (Spiegel et al. 2008; Kalinkovich et al. 2009). Of note, beta-adrenergic agonists have been shown to stimulate osteoclast activity (Arai, M. et al. 2003), which could have an effect on the osteoblast niche via two methods, a) physically by decreasing bone lining cells and releasing HSPCs, and b) chemically via the release of soluble factor (Kollet et al. 2006; Mansour et al. 2011). Calcium is an example of one such soluble factor, which serves as an attractant to HSPCs encouraging homing to the osteoblast niche (Adams et al. 2006). Hematopoietic cell egress from the marrow has also been linked to many systemic causes, including exercise, inflammation, bleeding, cytotoxic drugs, and psychological anxiety (reviewed in (Lapid et al. 2008). These data serve as reminders that hematopoiesis and the HME can be influenced

In the HME, cell-cell interactions influence cell fate decisions and mobility/homing; examples of such interactions include: Notch-1/Jagged-1, N-cadherin/N-cadherin and VLA-4/VCAM-1 (reviewed in (Coskun and Hirschi 2010). On the other hand, cell-matrix interactions influence not only cell behavior, but also cell anchorage to the niche. To date, the matrix proteins within the HME include: collagens (Types I, II, III, IV and X), glycoproteins (fibronectin, lamanin, nidogen, tenasin C, thrombospondin, vitronectin), PGs (perlecan, decorin, agrin) and the GAG hyaluronan (Bentley and Foidart 1980; Bentley 1982; Spooncer et al. 1983; Zuckerman and Wicha 1983; Zuckerman et al. 1985; Klein 1995; Ohta et al. 1998; Campbell et al. 2004; Mazzon et al. 2011). These matrix constituents can signal to hematopoietic cells through cell receptors such as: integrins, immunoglobulin-like molecules, cadherins, selectins, and mucins (Teixido et al. 1992; Coulombel et al. 1997; Levesque and Simmons 1999; Zhang, J. et al. 2003; Merzaban et al. 2011). Notably, the HME matrix network is not static, but is continually remodeled by different enzymes including

hematopoietic abnormalities (Pilia et al. 1996; Viviano et al. 2005).

by factors outside of the local environment.

**3.2.2 Cell and matrix influence** 

that the function of one cell type highly depends upon and is affected by the actions of the other (Khosla 2003). Thereby, the continual signaling between cells of the mesenchymal and hematopoietic lineages underlies the tightly coupled process of bone remodeling, and its uncoupling can lead to skeletal disorders such as osteoporosis, osteopetrosis, as well as calcium homeostasis imbalances. Such examples are also seen in mouse models; for example, in one model where osteoclasts are depleted, instead of having increased bone mass due to lack of resorption, there is decreased bone mass compared to wild type cohorts (Kong et al. 1999). Collectively, the intricate cross talk between cells within the HME can both positively and negatively affect the niche environment as well as hematopoiesis, and is a vast area if research that remains to be adequately explored.

#### **3.2 Soluble factors and the extracellular matrix in the niche**

#### **3.2.1 Cytokines, chemokines, growth factors, and neurotransmitters**

As referred to above, the hematopoietic and non-hematopoietic cells within the HME are surrounded in all dimensions by matrix components and soluble factors. The building blocks of the extracellular matrices found within the chondro-osseous environment can include collagens, proteoglycans (PGs; including the HSPGs) and their glycosaminoglycan (GAG) constituents and glycoproteins. Collagens generally provide structural support for cells in the niche by forming supramolecular aggregates around cells (Jacenko et al. 1991), while the PGs, such as the HSPGs, can trap and store soluble factors for presentation to local cells (as reviewed in (Rodgers et al. 2008). The amount and ratio of these molecules in the matrix also dictates the mechanical properties of the HME, which has recently become a topic of investigation in the stem cell field. For instance, matrix elasticity in the HME can influence fate choices of HSPCs (Holst et al. 2010), a phenomenon also reported with MSCs (as reviewed in (Discher et al. 2009). Thus, the matrix provides structural integrity to the HME, acts as a substrate for cell migration and anchorage, and actively regulates cell morphology, development and metabolic function (Peerani and Zandstra 2010). The cells in the HME receive information for maintenance, development, differentiation, etc. via cell-cell interactions, cell-matrix interactions, and exposure to variable concentrations and combinations of soluble factors, e.g. cytokines, chemokines, hormones, and growth factors. Many soluble factors have been implicated in hematopoiesis, such as CXCL-12, SCF, Fmsrelated tyrosine kinase 3 ligand (Flt-3L), thrombopoietin (TPO), FGF, G-CSF, GM-CSF, LIF, Wnt, BMP-4, IL-3, 6, 7, 8, 11, 12, 14, 15 (Guba et al. 1992; Heinrich et al. 1993; Verfaillie 1993; Funk et al. 1995; Rafii et al. 1997; Taichman et al. 1997; Peled et al. 1999; Majumdar et al. 2000; Ponomaryov et al. 2000; Petit et al. 2002; Avecilla et al. 2004; Kortesidis et al. 2005; Dar et al. 2006; Jung et al. 2006; Spiegel et al. 2007; Wittig et al. 2009), or in maintenance and quiescence of HSCs, e.g. Ang-1 and TGF (Eaves et al. 1991; Fortunel et al. 2000; Arai, F. et al. 2004) (cytokine functions reviewed in (Zhang, C.C. and Lodish 2008). The HME cell types discussed above are the primary sources of these soluble factors, however lymphocytes have also been shown to stimulate and suppress hematopoiesis through the release of different factors during both homeostasis and immune activation (Nathan et al. 1978; Bacigalupo et al. 1980; Mangan et al. 1982; Harada et al. 1985; Trinchieri et al. 1987; Crawford et al. 2010). Interestingly, many of these soluble factors are sequestered and presented by the matrix, specifically HSPGs, which have been described as key orchestrators of hematopoiesis (Bruno et al. 1995; Gupta et al. 1996; Gupta et al. 1998; Borghesi et al. 1999). This is particularly

that the function of one cell type highly depends upon and is affected by the actions of the other (Khosla 2003). Thereby, the continual signaling between cells of the mesenchymal and hematopoietic lineages underlies the tightly coupled process of bone remodeling, and its uncoupling can lead to skeletal disorders such as osteoporosis, osteopetrosis, as well as calcium homeostasis imbalances. Such examples are also seen in mouse models; for example, in one model where osteoclasts are depleted, instead of having increased bone mass due to lack of resorption, there is decreased bone mass compared to wild type cohorts (Kong et al. 1999). Collectively, the intricate cross talk between cells within the HME can both positively and negatively affect the niche environment as well as hematopoiesis, and is

As referred to above, the hematopoietic and non-hematopoietic cells within the HME are surrounded in all dimensions by matrix components and soluble factors. The building blocks of the extracellular matrices found within the chondro-osseous environment can include collagens, proteoglycans (PGs; including the HSPGs) and their glycosaminoglycan (GAG) constituents and glycoproteins. Collagens generally provide structural support for cells in the niche by forming supramolecular aggregates around cells (Jacenko et al. 1991), while the PGs, such as the HSPGs, can trap and store soluble factors for presentation to local cells (as reviewed in (Rodgers et al. 2008). The amount and ratio of these molecules in the matrix also dictates the mechanical properties of the HME, which has recently become a topic of investigation in the stem cell field. For instance, matrix elasticity in the HME can influence fate choices of HSPCs (Holst et al. 2010), a phenomenon also reported with MSCs (as reviewed in (Discher et al. 2009). Thus, the matrix provides structural integrity to the HME, acts as a substrate for cell migration and anchorage, and actively regulates cell morphology, development and metabolic function (Peerani and Zandstra 2010). The cells in the HME receive information for maintenance, development, differentiation, etc. via cell-cell interactions, cell-matrix interactions, and exposure to variable concentrations and combinations of soluble factors, e.g. cytokines, chemokines, hormones, and growth factors. Many soluble factors have been implicated in hematopoiesis, such as CXCL-12, SCF, Fmsrelated tyrosine kinase 3 ligand (Flt-3L), thrombopoietin (TPO), FGF, G-CSF, GM-CSF, LIF, Wnt, BMP-4, IL-3, 6, 7, 8, 11, 12, 14, 15 (Guba et al. 1992; Heinrich et al. 1993; Verfaillie 1993; Funk et al. 1995; Rafii et al. 1997; Taichman et al. 1997; Peled et al. 1999; Majumdar et al. 2000; Ponomaryov et al. 2000; Petit et al. 2002; Avecilla et al. 2004; Kortesidis et al. 2005; Dar et al. 2006; Jung et al. 2006; Spiegel et al. 2007; Wittig et al. 2009), or in maintenance and quiescence of HSCs, e.g. Ang-1 and TGF (Eaves et al. 1991; Fortunel et al. 2000; Arai, F. et al. 2004) (cytokine functions reviewed in (Zhang, C.C. and Lodish 2008). The HME cell types discussed above are the primary sources of these soluble factors, however lymphocytes have also been shown to stimulate and suppress hematopoiesis through the release of different factors during both homeostasis and immune activation (Nathan et al. 1978; Bacigalupo et al. 1980; Mangan et al. 1982; Harada et al. 1985; Trinchieri et al. 1987; Crawford et al. 2010). Interestingly, many of these soluble factors are sequestered and presented by the matrix, specifically HSPGs, which have been described as key orchestrators of hematopoiesis (Bruno et al. 1995; Gupta et al. 1996; Gupta et al. 1998; Borghesi et al. 1999). This is particularly

a vast area if research that remains to be adequately explored.

**3.2 Soluble factors and the extracellular matrix in the niche** 

**3.2.1 Cytokines, chemokines, growth factors, and neurotransmitters** 

 relevant to the collagen X mouse models that present with a disrupted collagen X network coupled with a decreased HSPG staining intensity at the chondro-osseous HME and diminished cytokine levels, leading to diminished B lymphopoiesis (Gress and Jacenko 2000; Jacenko et al. 2001; Jacenko et al. 2002; Sweeney et al. 2008; Sweeney et al. 2010). These findings imply that the structural defects in the matrix may lead to changes in the cytokine reservoirs, which in turn would negatively affect hematopoietic cell development. By extension, human diseases associated with altered matrix components at the HME may have altered hematopoiesis due to changes in cytokine availability, such as with Simpson-Golabi Behmel syndrome where alterations in the HSPG glypican-3 results in skeletal and hematopoietic abnormalities (Pilia et al. 1996; Viviano et al. 2005).

There is increasing evidence that the nervous system can also affect the immune system through neurotransmitter signaling. The bone and marrow are supplied with autonomic efferent and afferent sensory innervations, specifically at the epiphysis and metaphysis of long bone, which includes the chondro-osseous HME (**Fig. 1A**) (reviewed in (Mignini et al. 2003). Catecholamines, acetylcholine and peptide transmitters of neural and non-neural origin are released in the HME, which contribute to neuro-immune modulations. For example, signaling from the nervous system can regulate HSPC egress and repopulation of the marrow (Katayama et al. 2006; Spiegel et al. 2007), which has been shown to be coupled to the circadian rhythm (Mendez-Ferrer et al. 2008). Indeed, HSPCs have receptors for several neurotransmitters, which can stimulate cell proliferation (Spiegel et al. 2008; Kalinkovich et al. 2009). Of note, beta-adrenergic agonists have been shown to stimulate osteoclast activity (Arai, M. et al. 2003), which could have an effect on the osteoblast niche via two methods, a) physically by decreasing bone lining cells and releasing HSPCs, and b) chemically via the release of soluble factor (Kollet et al. 2006; Mansour et al. 2011). Calcium is an example of one such soluble factor, which serves as an attractant to HSPCs encouraging homing to the osteoblast niche (Adams et al. 2006). Hematopoietic cell egress from the marrow has also been linked to many systemic causes, including exercise, inflammation, bleeding, cytotoxic drugs, and psychological anxiety (reviewed in (Lapid et al. 2008). These data serve as reminders that hematopoiesis and the HME can be influenced by factors outside of the local environment.

#### **3.2.2 Cell and matrix influence**

In the HME, cell-cell interactions influence cell fate decisions and mobility/homing; examples of such interactions include: Notch-1/Jagged-1, N-cadherin/N-cadherin and VLA-4/VCAM-1 (reviewed in (Coskun and Hirschi 2010). On the other hand, cell-matrix interactions influence not only cell behavior, but also cell anchorage to the niche. To date, the matrix proteins within the HME include: collagens (Types I, II, III, IV and X), glycoproteins (fibronectin, lamanin, nidogen, tenasin C, thrombospondin, vitronectin), PGs (perlecan, decorin, agrin) and the GAG hyaluronan (Bentley and Foidart 1980; Bentley 1982; Spooncer et al. 1983; Zuckerman and Wicha 1983; Zuckerman et al. 1985; Klein 1995; Ohta et al. 1998; Campbell et al. 2004; Mazzon et al. 2011). These matrix constituents can signal to hematopoietic cells through cell receptors such as: integrins, immunoglobulin-like molecules, cadherins, selectins, and mucins (Teixido et al. 1992; Coulombel et al. 1997; Levesque and Simmons 1999; Zhang, J. et al. 2003; Merzaban et al. 2011). Notably, the HME matrix network is not static, but is continually remodeled by different enzymes including

Skeletogenesis and the Hematopoietic Niche 165

Fig. 2. The cells, matrix components and soluble factors within the chondro-osseous

and other marrow cells, such as lymphocytes. Additionally, progenitor cells such as hematopoietic stem/progenitor cells (HSPC), multipotent stromal cells (MSC) and nestin expressing (nestin +) MSC are represented. All of these cells serve as a source of secreted factors, including cytokines, chemokines and growth factors, as well as neurotransmitters from the sympathetic nervous system (SNS). Also note the gradients of oxygen (O2) and calcium (Ca++) released from the vasculature or remodeled bone respectively. Finally, the extracellular matrix (ECM) in the marrow and in the core of trabecular bone, consisting of hypertrophic cartilage derived lattice-like collagen X and HSPGs, can serve as a substrate for cell anchorage, migration, and/or signaling through cell-ECM binding and as a reservoirs of secreted factors.

hematopoietic microenvironment. The putative hematopoietic niche has been localized to the chondro-osseous junction (COJ) of endochondrally developing bones, e.g. the juncture of the growth plate (GP) hypertrophic chondrocytes and the trabecular bone (TB) and marrow (M). Boxed, a cartoon in higher magnification represents the chondro-osseous hematopoietic environment, which includes: osteoblasts, hypertrophic chondrocytes, endothelial cells, pericytes, CXCL-12 abundant cells (CAR), adipocytes, endosteal intercalating macrophages,

metalloproteinases, neutrophil elastase and hepranase. Matrix turnover can thus assist in the release of hematopoietic cells from the niche (Levesque et al. 2001; Heissig et al. 2002; Petit et al. 2002; Spiegel et al. 2008), as well as liberate bound soluble hematopoietic factors (Heissig et al. 2002; Spiegel et al. 2008). An example of one such cell-matrix interaction in the HME is the VLA-4/fibronectin binding between HSPCs and the matrix, which provides the hematopoietic cell with anchorage as well as proliferation stimuli (Weinstein et al. 1989; Klein et al. 1998; Sagar et al. 2006). Hyaluronan also impacts HSPC maintenance, propagation, homing and homeostasis via CD44 binding (Avigdor et al. 2004; Matrosova et al. 2004; Haylock and Nilsson 2006). Most recently, Mazzon et al. have found the binding between agrin, expressed by trabecular osteoblasts and MSCs in the niche, and HSPCs leads to survival and proliferation signals (Mazzon et al. 2011). Finally, mature plasma B cells homing back to the marrow via CXCL-12 signals are anchored to their marrow niche via matrix-bound ligands produced by local myeloid cells (O'Connor et al. 2004; Crowley et al. 2005; Ingold et al. 2005; Moreaux et al. 2005; Nagasawa 2006; Schwaller et al. 2007; Huard et al. 2008; Moreaux et al. 2009). In fact, it has been shown that this interaction maintains longlived antibody producing plasma B cells in the marrow by stimulating expression of antiapoptotic genes in the lymphocytes (O'Connor et al. 2004; Huard et al. 2008). Thus, the cellmatrix interactions in the marrow serve to support hematopoietic maintenance and development, as well as support the persistence of mature hematopoietic cells that have returned to the marrow.

#### **4. Summary and perspectives**

All the specialized cells of the blood are generated through hematopoiesis via the directed differentiation of HSCs. The bone marrow, which is the predominant hematopoietic tissue after birth (Aguila and Rowe 2005; Cumano and Godin 2007), is formed through EO, where the cartilage anlage serves as a transient template for trabecular bone, and defines the environment of the marrow stroma. Thereby, either directly or indirectly, the process of EO establishes the hematopoietic niche by providing the niche with both the structure matrix constituents and the cellular components (Jacenko et al. 1993; Taichman and Emerson 1994; Taichman et al. 1996; Taichman et al. 1997; Gress and Jacenko 2000; Calvi et al. 2001; Visnjic et al. 2001; Jacenko et al. 2002; Calvi et al. 2003; Zhang, J. et al. 2003; Visnjic et al. 2004; Jung et al. 2005; Jung et al. 2006; Zhu et al. 2007; Chan, C.K. et al. 2008; Sweeney et al. 2008; Wu et al. 2008; Raaijmakers et al. 2010; Sweeney et al. 2010). Many cell types, matrix components and soluble factors contribute to the HME (**Fig. 2**). Through several different methods, HSPCs have been visualized in the chondro-osseous HME (Nilsson et al. 1997; Nilsson et al. 2001; Yoshimoto et al. 2003; Arai, F. et al. 2004; Balduino et al. 2005; Kiel et al. 2005; Kohler et al. 2009; Xie et al. 2009), which is comprised of vasculature sinusoids, sympathetic nerves, complex and diverse matrix regions, as well as osteoblasts, hypertrophic chondrocytes, endothelial cells, pericytes, CXCL-12 expressing cells, adipocytes, nestin+ cells, MSCs, macrophages intercalated in the endosteum, and cells of the immune system, both developing and recirculating. The cells of the HME express the cytokines, growth factors and chemokines utilized throughout hematopoiesis, as well as the matrix molecules that provides structural support, cell-matrix signaling and reservoirs of soluble factors (**Fig. 2**). We propose that the chondro-oseous HME is not static, but is continuously changing in response to various systemic influences (Lapid et al. 2008), as well as to remodeling of the hybrid trabecular bone-hypertrophic cartilage spicules into mature secondary bone (**Fig. 1C & 2**). During remodeling of the HME, both cells and

metalloproteinases, neutrophil elastase and hepranase. Matrix turnover can thus assist in the release of hematopoietic cells from the niche (Levesque et al. 2001; Heissig et al. 2002; Petit et al. 2002; Spiegel et al. 2008), as well as liberate bound soluble hematopoietic factors (Heissig et al. 2002; Spiegel et al. 2008). An example of one such cell-matrix interaction in the HME is the VLA-4/fibronectin binding between HSPCs and the matrix, which provides the hematopoietic cell with anchorage as well as proliferation stimuli (Weinstein et al. 1989; Klein et al. 1998; Sagar et al. 2006). Hyaluronan also impacts HSPC maintenance, propagation, homing and homeostasis via CD44 binding (Avigdor et al. 2004; Matrosova et al. 2004; Haylock and Nilsson 2006). Most recently, Mazzon et al. have found the binding between agrin, expressed by trabecular osteoblasts and MSCs in the niche, and HSPCs leads to survival and proliferation signals (Mazzon et al. 2011). Finally, mature plasma B cells homing back to the marrow via CXCL-12 signals are anchored to their marrow niche via matrix-bound ligands produced by local myeloid cells (O'Connor et al. 2004; Crowley et al. 2005; Ingold et al. 2005; Moreaux et al. 2005; Nagasawa 2006; Schwaller et al. 2007; Huard et al. 2008; Moreaux et al. 2009). In fact, it has been shown that this interaction maintains longlived antibody producing plasma B cells in the marrow by stimulating expression of antiapoptotic genes in the lymphocytes (O'Connor et al. 2004; Huard et al. 2008). Thus, the cellmatrix interactions in the marrow serve to support hematopoietic maintenance and development, as well as support the persistence of mature hematopoietic cells that have

All the specialized cells of the blood are generated through hematopoiesis via the directed differentiation of HSCs. The bone marrow, which is the predominant hematopoietic tissue after birth (Aguila and Rowe 2005; Cumano and Godin 2007), is formed through EO, where the cartilage anlage serves as a transient template for trabecular bone, and defines the environment of the marrow stroma. Thereby, either directly or indirectly, the process of EO establishes the hematopoietic niche by providing the niche with both the structure matrix constituents and the cellular components (Jacenko et al. 1993; Taichman and Emerson 1994; Taichman et al. 1996; Taichman et al. 1997; Gress and Jacenko 2000; Calvi et al. 2001; Visnjic et al. 2001; Jacenko et al. 2002; Calvi et al. 2003; Zhang, J. et al. 2003; Visnjic et al. 2004; Jung et al. 2005; Jung et al. 2006; Zhu et al. 2007; Chan, C.K. et al. 2008; Sweeney et al. 2008; Wu et al. 2008; Raaijmakers et al. 2010; Sweeney et al. 2010). Many cell types, matrix components and soluble factors contribute to the HME (**Fig. 2**). Through several different methods, HSPCs have been visualized in the chondro-osseous HME (Nilsson et al. 1997; Nilsson et al. 2001; Yoshimoto et al. 2003; Arai, F. et al. 2004; Balduino et al. 2005; Kiel et al. 2005; Kohler et al. 2009; Xie et al. 2009), which is comprised of vasculature sinusoids, sympathetic nerves, complex and diverse matrix regions, as well as osteoblasts, hypertrophic chondrocytes, endothelial cells, pericytes, CXCL-12 expressing cells, adipocytes, nestin+ cells, MSCs, macrophages intercalated in the endosteum, and cells of the immune system, both developing and recirculating. The cells of the HME express the cytokines, growth factors and chemokines utilized throughout hematopoiesis, as well as the matrix molecules that provides structural support, cell-matrix signaling and reservoirs of soluble factors (**Fig. 2**). We propose that the chondro-oseous HME is not static, but is continuously changing in response to various systemic influences (Lapid et al. 2008), as well as to remodeling of the hybrid trabecular bone-hypertrophic cartilage spicules into mature secondary bone (**Fig. 1C & 2**). During remodeling of the HME, both cells and

returned to the marrow.

**4. Summary and perspectives** 

Fig. 2. The cells, matrix components and soluble factors within the chondro-osseous hematopoietic microenvironment. The putative hematopoietic niche has been localized to the chondro-osseous junction (COJ) of endochondrally developing bones, e.g. the juncture of the growth plate (GP) hypertrophic chondrocytes and the trabecular bone (TB) and marrow (M). Boxed, a cartoon in higher magnification represents the chondro-osseous hematopoietic environment, which includes: osteoblasts, hypertrophic chondrocytes, endothelial cells, pericytes, CXCL-12 abundant cells (CAR), adipocytes, endosteal intercalating macrophages, and other marrow cells, such as lymphocytes. Additionally, progenitor cells such as hematopoietic stem/progenitor cells (HSPC), multipotent stromal cells (MSC) and nestin expressing (nestin +) MSC are represented. All of these cells serve as a source of secreted factors, including cytokines, chemokines and growth factors, as well as neurotransmitters from the sympathetic nervous system (SNS). Also note the gradients of oxygen (O2) and calcium (Ca++) released from the vasculature or remodeled bone respectively. Finally, the extracellular matrix (ECM) in the marrow and in the core of trabecular bone, consisting of hypertrophic cartilage derived lattice-like collagen X and HSPGs, can serve as a substrate for cell anchorage, migration, and/or signaling through cell-ECM binding and as a reservoirs of secreted factors.

Skeletogenesis and the Hematopoietic Niche 167

hematopoietic niche will continue to provide details on necessary niche components, which may assist in the understanding of other stem cell niches, including the vascular, skin, hair, and neural niches, and provide therapeutic cues for immuno-osseous diseases that present with skeletal defects and altered hematopoiesis, such as McKusick type metaphyseal chondrodysplasia (cartilage-hair hypoplasia; CHH), Shwachmen-Diamond syndrome, Schimke dysplasia (Spranger et al. 1991; Kuijpers et al. 2004; Hermanns et al. 2005), and

Abkowitz, J. L., A. E. Robinson, S. Kale, M. W. Long & J. Chen (2003). "Mobilization of

Adams, G. B., K. T. Chabner, I. R. Alley, D. P. Olson, Z. M. Szczepiorkowski, M. C.

Aguila, H. L. & D. W. Rowe (2005). "Skeletal development, bone remodeling, and

Akintoye, S. O., T. Lam, S. Shi, J. Brahim, M. T. Collins & P. G. Robey (2006). "Skeletal site-

Allouche, M. & A. Bikfalvi (1995). "The role of fibroblast growth factor-2 (FGF-2) in

Alvarez, J., M. Balbin, M. Fernandez & J. M. Lopez (2001). "Collagen metabolism is markedly

Arai, F., A. Hirao, M. Ohmura, H. Sato, S. Matsuoka, K. Takubo, K. Ito, G. Y. Koh & T. Suda

Arai, M., T. Nagasawa, Y. Koshihara, S. Yamamoto & A. Togari (2003). "Effects of beta-

Augello, A., T. B. Kurth & C. De Bari (2010). "Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches." *Eur Cell Mater* 20: 121-133 Avecilla, S. T., K. Hattori, B. Heissig, R. Tejada, F. Liao, K. Shido, D. K. Jin, S. Dias, F. Zhang,

Avigdor, A., P. Goichberg, S. Shivtiel, A. Dar, A. Peled, S. Samira, O. Kollet, R. Hershkoviz,

stem/progenitor cells to bone marrow." *Blood* 103(8): 2981-2989

hematopoietic stem cells during homeostasis and after cytokine exposure." *Blood*

Poznansky, C. H. Kos, M. R. Pollak, E. M. Brown & D. T. Scadden (2006). "Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor."

specific characterization of orofacial and iliac crest human bone marrow stromal

altered in the hypertrophic cartilage of growth plates from rats with growth impairment secondary to chronic renal failure." *J Bone Miner Res* 16(3): 511-524 Ara, T., K. Tokoyoda, T. Sugiyama, T. Egawa, K. Kawabata & T. Nagasawa (2003). "Long-

term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing

(2004). "Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence

adrenergic agonists on bone-resorbing activity in human osteoclast-like cells."

T. E. Hartman, N. R. Hackett, R. G. Crystal, L. Witte, D. J. Hicklin, P. Bohlen, D. Eaton, D. Lyden, F. de Sauvage & S. Rafii (2004). "Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for

R. Alon, I. Hardan, H. Ben-Hur, D. Naor, A. Nagler & T. Lapidot (2004). "CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+

others.

**5. References** 

102(4): 1249-1253

*Nature* 439(7076): 599-603

hematopoiesis." *Immunol Rev* 208: 7-18

cells in same individuals." *Bone* 38(6): 758-768

hematopoiesis." *Prog Growth Factor Res* 6(1): 35-48

in the bone marrow niche." *Cell* 118(2): 149-161

*Biochim Biophys Acta* 1640(2-3): 137-142

thrombopoiesis." *Nat Med* 10(1): 64-71

bone marrow during ontogeny." *Immunity* 19(2): 257-267

soluble factors are released into the milieu; for example matrix degrading enzymes release HSPCs for egress, and the combined activity of osteoclasts and enzymes release soluble factors from bone, including the trabecular bone with a collagen X/HSPG core (**Fig. 2**). Thus, the chondro-osseous HME is a continually active site with intrinsic and systemic signals influencing the cellular cross talk that ensures proper quiescence, maintenance, and differentiation of the HSPCs.

As itemized in **Table 1** and discussed above, various mouse models have revealed important cell and matrix players in the HME, while others have implicated the importance of proper cell cycle (Walkley et al. 2005; Walkley et al. 2007), transcription (Corradi et al. 2003; Purton et al. 2006; Walkley et al. 2007; Kieslinger et al. 2010), cell-cell communication (Larsson et al. 2008), and survival signals (Youn et al. 2008; Kwon et al. 2010) in the HME (**Table 1**). Still, the exact cellular make up and location of the HME is continually under debate, though most agree the cells of the osteoblast and vascular niches are important players in hematopoiesis. The possibility of osteoblast and vascular niches spatially overlapping or having the ability to provide some compensation for each other to some extent, is another intriguing theory. Evidence for this is observed with the biglycan deficient mouse model that presents with reduced bone, yet intact hematopoiesis (Kiel et al. 2007), as well as with the recently identified CAR cells that unite the osteoblast and vascular niches in the chondro-osseous HME by the observation that they are in contact with 90% of HSPCs throughout the trabecular bone region and the marrow sinusoidal region (Sugiyama et al. 2006; Omatsu et al. 2010). Additionally, there is similarity in the expression of hematopoietic soluble factors between the osteoblasts, endothelial cells, and CAR cells, such as CXCL-12 implicated in the homing, growth, development and maintenance of hematopoietic cells (Peled et al. 1999; Ponomaryov et al. 2000; Tokoyoda et al. 2004; Broxmeyer et al. 2005; Kortesidis et al. 2005; Dar et al. 2006; Sugiyama et al. 2006). Moreover, Medici et al. have confirmed an endothelial to osteoblast and chondrocyte transition in vivo, further supporting a cell interchange and overlap theory (Medici et al. 2010). In contrast, there is also evidence that the osteoblast and vascular niches provide different roles in hematopoiesis, e.g. a quiescence and maintenance role verses a differentiation and egress role (Lord et al. 1975; Shackney et al. 1975; Gong 1978; Nilsson et al. 2001; Heissig et al. 2002; Arai, F. et al. 2004; Balduino et al. 2005; Jang and Sharkis 2007; Bourke et al. 2009). Further, although these niches are proximal in the chondro-oseous region, mathematical modeling has predicted a layer of only two myeloid cells is sufficient to deplete most oxygen provided by a near by sinusoid (Chow et al. 2001). Thus, the local environment within each niche may differ significantly in chemical signals, such as with oxygen and calcium (**Fig. 2**).

Overall, the research generated in the hematopoietic niche field is beginning to shed light on many hematologic disorders, such as myelodysplasia, myeloproliferative syndromes and leukemias that seem to be influenced by the quality of the marrow environment (Walkley et al. 2007; Walkley et al. 2007; Raaijmakers et al. 2010). Further information on niche components, specifically the matrix molecules, will assist in generating bio-mimicking composites necessary for in vitro culture and expansion of patient specific hematopoietic tissues, for such clinical applications as autologous marrow transfers. The past sixty years of hematopoietic biology research has increased our understanding of marrow stromal cell types, as well as the three-dimensional regions that provide structure and organization of cell signaling for the maintenance and propagation of HSPCs. The study of the hematopoietic niche will continue to provide details on necessary niche components, which may assist in the understanding of other stem cell niches, including the vascular, skin, hair, and neural niches, and provide therapeutic cues for immuno-osseous diseases that present with skeletal defects and altered hematopoiesis, such as McKusick type metaphyseal chondrodysplasia (cartilage-hair hypoplasia; CHH), Shwachmen-Diamond syndrome, Schimke dysplasia (Spranger et al. 1991; Kuijpers et al. 2004; Hermanns et al. 2005), and others.

#### **5. References**

166 Advances in Hematopoietic Stem Cell Research

soluble factors are released into the milieu; for example matrix degrading enzymes release HSPCs for egress, and the combined activity of osteoclasts and enzymes release soluble factors from bone, including the trabecular bone with a collagen X/HSPG core (**Fig. 2**). Thus, the chondro-osseous HME is a continually active site with intrinsic and systemic signals influencing the cellular cross talk that ensures proper quiescence, maintenance, and

As itemized in **Table 1** and discussed above, various mouse models have revealed important cell and matrix players in the HME, while others have implicated the importance of proper cell cycle (Walkley et al. 2005; Walkley et al. 2007), transcription (Corradi et al. 2003; Purton et al. 2006; Walkley et al. 2007; Kieslinger et al. 2010), cell-cell communication (Larsson et al. 2008), and survival signals (Youn et al. 2008; Kwon et al. 2010) in the HME (**Table 1**). Still, the exact cellular make up and location of the HME is continually under debate, though most agree the cells of the osteoblast and vascular niches are important players in hematopoiesis. The possibility of osteoblast and vascular niches spatially overlapping or having the ability to provide some compensation for each other to some extent, is another intriguing theory. Evidence for this is observed with the biglycan deficient mouse model that presents with reduced bone, yet intact hematopoiesis (Kiel et al. 2007), as well as with the recently identified CAR cells that unite the osteoblast and vascular niches in the chondro-osseous HME by the observation that they are in contact with 90% of HSPCs throughout the trabecular bone region and the marrow sinusoidal region (Sugiyama et al. 2006; Omatsu et al. 2010). Additionally, there is similarity in the expression of hematopoietic soluble factors between the osteoblasts, endothelial cells, and CAR cells, such as CXCL-12 implicated in the homing, growth, development and maintenance of hematopoietic cells (Peled et al. 1999; Ponomaryov et al. 2000; Tokoyoda et al. 2004; Broxmeyer et al. 2005; Kortesidis et al. 2005; Dar et al. 2006; Sugiyama et al. 2006). Moreover, Medici et al. have confirmed an endothelial to osteoblast and chondrocyte transition in vivo, further supporting a cell interchange and overlap theory (Medici et al. 2010). In contrast, there is also evidence that the osteoblast and vascular niches provide different roles in hematopoiesis, e.g. a quiescence and maintenance role verses a differentiation and egress role (Lord et al. 1975; Shackney et al. 1975; Gong 1978; Nilsson et al. 2001; Heissig et al. 2002; Arai, F. et al. 2004; Balduino et al. 2005; Jang and Sharkis 2007; Bourke et al. 2009). Further, although these niches are proximal in the chondro-oseous region, mathematical modeling has predicted a layer of only two myeloid cells is sufficient to deplete most oxygen provided by a near by sinusoid (Chow et al. 2001). Thus, the local environment within each niche may

differ significantly in chemical signals, such as with oxygen and calcium (**Fig. 2**).

Overall, the research generated in the hematopoietic niche field is beginning to shed light on many hematologic disorders, such as myelodysplasia, myeloproliferative syndromes and leukemias that seem to be influenced by the quality of the marrow environment (Walkley et al. 2007; Walkley et al. 2007; Raaijmakers et al. 2010). Further information on niche components, specifically the matrix molecules, will assist in generating bio-mimicking composites necessary for in vitro culture and expansion of patient specific hematopoietic tissues, for such clinical applications as autologous marrow transfers. The past sixty years of hematopoietic biology research has increased our understanding of marrow stromal cell types, as well as the three-dimensional regions that provide structure and organization of cell signaling for the maintenance and propagation of HSPCs. The study of the

differentiation of the HSPCs.


Skeletogenesis and the Hematopoietic Niche 169

Bruno, E., S. D. Luikart, M. W. Long & R. Hoffman (1995). "Marrow-derived heparan sulfate

Burkhardt, R., G. Kettner, W. Bohm, M. Schmidmeier, R. Schlag, B. Frisch, B. Mallmann, W.

Butler, J. M., D. J. Nolan, E. L. Vertes, B. Varnum-Finney, H. Kobayashi, A. T. Hooper, M.

Calvi, L. M., G. B. Adams, K. W. Weibrecht, J. M. Weber, D. P. Olson, M. C. Knight, R. P.

Calvi, L. M., N. A. Sims, J. L. Hunzelman, M. C. Knight, A. Giovannetti, J. M. Saxton, H. M.

Chan, C. K., C. C. Chen, C. A. Luppen, J. B. Kim, A. T. Deboer, K. Wei, J. A. Helms, C. J. Kuo,

Chan, D. & O. Jacenko (1998). "Phenotypic and biochemical consequences of collagen X

Chang, M. K., L. J. Raggatt, K. A. Alexander, J. S. Kuliwaba, N. L. Fazzalari, K. Schroder, E.

Compston, J. E. (2002). "Bone marrow and bone: a functional unit." *J Endocrinol* 173(3): 387-

Corradi, A., L. Croci, V. Broccoli, S. Zecchini, S. Previtali, W. Wurst, S. Amadio, R. Maggi, A.

peripheral neuropathy in Ebf2-null mice." *Development* 130(2): 401-410 Corre, J., C. Barreau, B. Cousin, J. P. Chavoin, D. Caton, G. Fournial, L. Penicaud, L. Casteilla

comparative histomorphometric study." *Bone* 8(3): 157-164

hematopoietic stem cells." *Cell Stem Cell* 6(3): 251-264

haematopoietic stem-cell niche formation." *Nature* 

mutations in mice and humans." *Matrix Biol* 17(3): 169-184

*Exp Hematol* 23(11): 1212-1217

niche." *Nature* 425(6960): 841-846

mice." *Am J Pathol* 164(2): 487-499

*Biophys J* 81(2): 675-684

208(2): 282-288

394

proteoglycan mediates the adhesion of hematopoietic progenitor cells to cytokines."

Eisenmenger & T. Gilg (1987). "Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a

Seandel, K. Shido, I. A. White, M. Kobayashi, L. Witte, C. May, C. Shawber, Y. Kimura, J. Kitajewski, Z. Rosenwaks, I. D. Bernstein & S. Rafii (2010). "Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent

Martin, E. Schipani, P. Divieti, F. R. Bringhurst, L. A. Milner, H. M. Kronenberg & D. T. Scadden (2003). "Osteoblastic cells regulate the haematopoietic stem cell

Kronenberg, R. Baron & E. Schipani (2001). "Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone." *J Clin Invest* 107(3): 277-286 Campbell, M. R., C. J. Gress, E. H. Appleman & O. Jacenko (2004). "Chicken collagen X

regulatory sequences restrict transgene expression to hypertrophic cartilage in

D. L. Kraft & I. L. Weissman (2008). "Endochondral ossification is required for

R. Maylin, V. M. Ripoll, D. A. Hume & A. R. Pettit (2008). "Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo." *J Immunol* 181(2): 1232-1244 Chow, D. C., L. A. Wenning, W. M. Miller & E. T. Papoutsakis (2001). "Modeling pO(2)

distributions in the bone marrow hematopoietic compartment. I. Krogh's model."

Quattrini & G. G. Consalez (2003). "Hypogonadotropic hypogonadism and

& P. Laharrague (2006). "Human subcutaneous adipose cells support complete differentiation but not self-renewal of hematopoietic progenitors." *J Cell Physiol*


Bacigalupo, A., M. Podesta, M. C. Mingari, L. Moretta, M. T. Van Lint & A. Marmont (1980).

Balduino, A., S. P. Hurtado, P. Frazao, C. M. Takiya, L. M. Alves, L. E. Nasciutti, M. C. El-

Belaid-Choucair, Z., Y. Lepelletier, G. Poncin, A. Thiry, C. Humblet, M. Maachi, A. Beaulieu,

Benayahu, D., A. Fried, D. Zipori & S. Wientroub (1991). "Subpopulations of marrow

Benayahu, D., M. Horowitz, D. Zipori & S. Wientroub (1992). "Hemopoietic functions of

Bentley, S. A. (1982). "Collagen synthesis by bone marrow stromal cells: a quantitative

Bentley, S. A. & J. M. Foidart (1980). "Some properties of marrow derived adherent cells in

Bi, Y., C. H. Stuelten, T. Kilts, S. Wadhwa, R. V. Iozzo, P. G. Robey, X. D. Chen & M. F.

Bianco, P., M. Costantini, L. C. Dearden & E. Bonucci (1988). "Alkaline phosphatase positive precursors of adipocytes in the human bone marrow." *Br J Haematol* 68(4): 401-403 Bianco, P., M. Riminucci, S. Kuznetsov & P. G. Robey (1999). "Multipotential cells in the

Blin-Wakkach, C., A. Wakkach, P. M. Sexton, N. Rochet & G. F. Carle (2004). "Hematological

Bohensky, J., I. M. Shapiro, S. Leshinsky, S. P. Terkhorn, C. S. Adams & V. Srinivas (2007).

Borghesi, L. A., Y. Yamashita & P. W. Kincade (1999). "Heparan sulfate proteoglycans mediate interleukin-7-dependent B lymphopoiesis." *Blood* 93(1): 140-148 Bourke, V. A., C. J. Watchman, J. D. Reith, M. L. Jorgensen, A. Dieudonne & W. E. Bolch

Young (2005). "Extracellular matrix proteoglycans control the fate of bone marrow

bone marrow stroma: regulation in the context of organ physiology." *Crit Rev* 

defects in the oc/oc mouse, a model of infantile malignant osteopetrosis." *Leukemia*

"HIF-1 regulation of chondrocyte apoptosis: induction of the autophagic pathway."

(2009). "Spatial gradients of blood vessels and hematopoietic stem and progenitor cells within the marrow cavities of the human skeleton." *Blood* 114(19): 4077-4080 Broxmeyer, H. E., C. M. Orschell, D. W. Clapp, G. Hangoc, S. Cooper, P. A. Plett, W. C. Liles,

X. Li, B. Graham-Evans, T. B. Campbell, G. Calandra, G. Bridger, D. C. Dale & E. F. Srour (2005). "Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist." *J Exp Med* 201(8): 1307-1318

marrow-derived osteogenic cells." *Calcif Tissue Int* 51(3): 195-201

lymphocytes." *J Immunol* 125(4): 1449-1453

*Tissue Res* 319(2): 255-266

study." *Br J Haematol* 50(3): 491-497

tissue culture." *Blood* 56(6): 1006-1012

*Eukaryot Gene Expr* 9(2): 159-173

18(9): 1505-1511

*Autophagy* 3(3): 207-214

stromal cells." *J Biol Chem* 280(34): 30481-30489

1564

"Immune suppression of hematopoiesis in aplastic anemia: activity of T-gamma

Cheikh & R. Borojevic (2005). "Bone marrow subendosteal microenvironment harbours functionally distinct haemosupportive stromal cell populations." *Cell* 

E. Schneider, A. Briquet, P. Mineur, C. Lambert, D. Mendes-Da-Cruz, M. L. Ahui, V. Asnafi, M. Dy, J. Boniver, B. V. Nusgens, O. Hermine & M. P. Defresne (2008). "Human bone marrow adipocytes block granulopoiesis through neuropilin-1 induced granulocyte colony-stimulating factor inhibition." *Stem Cells* 26(6): 1556-

stromal cells share a variety of osteoblastic markers." *Calcif Tissue Int* 49(3): 202-207


Skeletogenesis and the Hematopoietic Niche 171

Farnum, C. E. & N. J. Wilsman (1989). "Cellular turnover at the chondro-osseous junction of

Fortunel, N., J. Hatzfeld, L. Aoustin, P. Batard, K. Ducos, M. N. Monier, A. Charpentier & A.

Friedenstein, A. J., R. K. Chailakhjan & K. S. Lalykina (1970). "The development of fibroblast

Friedenstein, A. J., R. K. Chailakhyan & U. V. Gerasimov (1987). "Bone marrow osteogenic

Friedenstein, A. J., R. K. Chailakhyan, N. V. Latsinik, A. F. Panasyuk & I. V. Keiliss-Borok

Friedenstein, A. J., J. F. Gorskaja & N. N. Kulagina (1976). "Fibroblast precursors in normal and irradiated mouse hematopoietic organs." *Exp Hematol* 4(5): 267-274 Friedenstein, A. J., N. W. Latzinik, A. G. Grosheva & U. F. Gorskaya (1982). "Marrow

Funk, P. E., R. P. Stephan & P. L. Witte (1995). "Vascular cell adhesion molecule 1-positive

Galotto, M., G. Campanile, G. Robino, F. D. Cancedda, P. Bianco & R. Cancedda (1994).

Gekas, C., F. Dieterlen-Lievre, S. H. Orkin & H. K. Mikkola (2005). "The placenta is a niche

Gibson, G. J. & M. H. Flint (1985). "Type X collagen synthesis by chick sternal cartilage and its relationship to endochondral development." *J Cell Biol* 101(1): 277-284 Godman, G. C. & K. R. Porter (1960). "Chondrogenesis, studied with the electron

Gong, J. K. (1978). "Endosteal marrow: a rich source of hematopoietic stem cells." *Science*

Gordon, M. Y., G. P. Riley & D. Clarke (1988). "Heparan sulfate is necessary for adhesive

Grimaud, E., F. Blanchard, C. Charrier, F. Gouin, F. Redini & D. Heymann (2002).

vascular sprouts during osteogenesis." *Cytokine* 20(5): 224-230

interactions between human early hemopoietic progenitor cells and the extracellular matrix of the marrow microenvironment." *Leukemia* 2(12): 804-809 Gress, C. J. & O. Jacenko (2000). "Growth plate compressions and altered hematopoiesis in

"Leukaemia inhibitory factor (lif) is expressed in hypertrophic chondrocytes and

cultured cells in porous sponges." *Exp Hematol* 10(2): 217-227

for hematopoietic stem cells." *Dev Cell* 8(3): 365-375

microscope." *J Biophys Biochem Cytol* 8: 719-760

collagen X null mice." *J Cell Biol* 149(4): 983-993

*Orthop Res* 7(5): 654-666

*Hematol J* 1(2): 126-135

*Tissue Kinet* 3(4): 393-403

*Tissue Kinet* 20(3): 263-272

17(4): 331-340

86(7): 2661-2671

*Miner Res* 9(8): 1239-1249

199(4336): 1443-1445

growth plate cartilage: analysis by serial sections at the light microscopical level." *J* 

Hatzfeld (2000). "Specific dose-response effects of TGF-beta1 on developmentally distinct hematopoietic stem/progenitor cells from human umbilical cord blood."

colonies in monolayer cultures of guinea-pig bone marrow and spleen cells." *Cell* 

stem cells: in vitro cultivation and transplantation in diffusion chambers." *Cell* 

(1974). "Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo." *Transplantation*

microenvironment transfer by heterotopic transplantation of freshly isolated and

reticular cells express interleukin-7 and stem cell factor in the bone marrow." *Blood*

"Hypertrophic chondrocytes undergo further differentiation to osteoblast-like cells and participate in the initial bone formation in developing chick embryo." *J Bone* 


Coskun, S. & K. K. Hirschi (2010). "Establishment and regulation of the HSC niche: Roles of

Coulombel, L., I. Auffray, M. H. Gaugler & M. Rosemblatt (1997). "Expression and function of integrins on hematopoietic progenitor cells." *Acta Haematol* 97(1-2): 13-21 Crawford, L. J., R. Peake, S. Price, T. C. Morris & A. E. Irvine (2010). "Adiponectin is

Crisan, M., S. Yap, L. Casteilla, C. W. Chen, M. Corselli, T. S. Park, G. Andriolo, B. Sun, B.

Crowley, J. E., L. S. Treml, J. E. Stadanlick, E. Carpenter & M. P. Cancro (2005). "Homeostatic

Cumano, A., F. Dieterlen-Lievre & I. Godin (1996). "Lymphoid potential, probed before

Cumano, A. & I. Godin (2007). "Ontogeny of the hematopoietic system." *Annu Rev Immunol*

Dar, A., O. Kollet & T. Lapidot (2006). "Mutual, reciprocal SDF-1/CXCR4 interactions

de Bruijn, M. F., X. Ma, C. Robin, K. Ottersbach, M. J. Sanchez & E. Dzierzak (2002).

Dexter, T. M., T. D. Allen & L. G. Lajtha (1977). "Conditions controlling the proliferation of

Dexter, T. M., T. D. Allen, L. G. Lajtha, R. Schofield & B. I. Lord (1973). "Stimulation of

Discher, D. E., D. J. Mooney & P. W. Zandstra (2009). "Growth factors, matrices, and forces

Dominici, M., V. Rasini, R. Bussolari, X. Chen, T. J. Hofmann, C. Spano, D. Bernabei, E.

Eaves, C. J., J. D. Cashman, R. J. Kay, G. J. Dougherty, T. Otsuka, L. A. Gaboury, D. E.

haemopoietic stem cells in vitro." *J Cell Physiol* 91(3): 335-344

combine and control stem cells." *Science* 324(5935): 1673-1677

by stromal cells within the adherent layer." *Blood* 78(1): 110-117

family of receptors and ligands." *Semin Immunol* 17(3): 193-199

229-242

*Biol* 88(4): 807-811

*Stem Cell* 3(3): 301-313

mouse aorta." *Immunity* 16(5): 673-683

radioablation." *Blood* 114(11): 2333-2343

86(6): 907-916

25: 745-785

975

461-473

osteoblastic and vascular compartments." *Birth Defects Res C Embryo Today* 90(4):

produced by lymphocytes and is a negative regulator of granulopoiesis." *J Leukoc* 

Zheng, L. Zhang, C. Norotte, P. N. Teng, J. Traas, R. Schugar, B. M. Deasy, S. Badylak, H. J. Buhring, J. P. Giacobino, L. Lazzari, J. Huard & B. Peault (2008). "A perivascular origin for mesenchymal stem cells in multiple human organs." *Cell* 

niche specification among naive and activated B cells: a growing role for the BLyS

circulation in mouse, is restricted to caudal intraembryonic splanchnopleura." *Cell*

between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice." *Exp Hematol* 34(8): 967-

"Hematopoietic stem cells localize to the endothelial cell layer in the midgestation

differentiation and proliferation of haemopoietic cells in vitro." *J Cell Physiol* 82(3):

Veronesi, F. Bertoni, P. Paolucci, P. Conte & E. M. Horwitz (2009). "Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow

Hogge, P. M. Lansdorp, A. C. Eaves & R. K. Humphries (1991). "Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced


Skeletogenesis and the Hematopoietic Niche 173

Horwitz, E. M., K. Le Blanc, M. Dominici, I. Mueller, I. Slaper-Cortenbach, F. C. Marini, R. J.

Hotamisligil, G. S., N. S. Shargill & B. M. Spiegelman (1993). "Adipose expression of tumor

Huard, B., T. McKee, C. Bosshard, S. Durual, T. Matthes, S. Myit, O. Donze, C. Frossard, C.

Jacenko, O., D. Chan, A. Franklin, S. Ito, C. B. Underhill, J. F. Bateman & M. R. Campbell

Jacenko, O., S. Ito & B. R. Olsen (1996). "Skeletal and hematopoietic defects in mice

Jacenko, O., P. A. LuValle & B. R. Olsen (1993). "Spondylometaphyseal dysplasia in mice

Jacenko, O., B. R. Olsen & P. LuValle (1991). "Organization and regulation of collagen

Jacenko, O., D. W. Roberts, M. R. Campbell, P. M. McManus, C. J. Gress & Z. Tao (2002).

Jacobsen, K. & D. G. Osmond (1990). "Microenvironmental organization and stromal cell

James, C. G., L. A. Stanton, H. Agoston, V. Ulici, T. M. Underhill & F. Beier (2010). "Genome-

Jang, Y. Y. & S. J. Sharkis (2007). "A low level of reactive oxygen species selects for primitive

Janzen, V., R. Forkert, H. E. Fleming, Y. Saito, M. T. Waring, D. M. Dombkowski, T. Cheng,

plasma cell niches in human mucosa." *J Clin Invest* 118(8): 2887-2895 Ingold, K., A. Zumsteg, A. Tardivel, B. Huard, Q. G. Steiner, T. G. Cachero, F. Qiang, L.

distribution in transgenic mice." *Am J Pathol* 159(6): 2257-2269

transgenic for collagen X." *Ann N Y Acad Sci* 785: 278-280

transgenic for collagen X." *Am J Pathol* 160(6): 2019-2034

bone transition." *Nature* 365(6441): 56-61

genes." *Crit Rev Eukaryot Gene Expr* 1(4): 327-353

progenitor cells." *Nat Biotechnol* 28(10): 1123-1128

*Cytotherapy* 7(5): 393-395

*Exp Med* 201(9): 1375-1383

*Immunol* 20(11): 2395-2404

*One* 5(1): e8693

3056-3063

259(5091): 87-91

elasticity provides mechanical signals for the expansion of hemopoietic stem and

Deans, D. S. Krause & A. Keating (2005). "Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement."

necrosis factor-alpha: direct role in obesity-linked insulin resistance." *Science*

Chizzolini, C. Favre, R. Zubler, J. P. Guyot, P. Schneider & E. Roosnek (2008). "APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create

Gorelik, S. L. Kalled, H. Acha-Orbea, P. D. Rennert, J. Tschopp & P. Schneider (2005). "Identification of proteoglycans as the APRIL-specific binding partners." *J* 

(2001). "A dominant interference collagen X mutation disrupts hypertrophic chondrocyte pericellular matrix and glycosaminoglycan and proteoglycan

carrying a dominant negative mutation in a matrix protein specific for cartilage-to-

"Linking hematopoiesis to endochondral skeletogenesis through analysis of mice

associations of B lymphocyte precursor cells in mouse bone marrow." *Eur J* 

wide analyses of gene expression during mouse endochondral ossification." *PLoS* 

hematopoietic stem cells that may reside in the low-oxygenic niche." *Blood* 110(8):

R. A. DePinho, N. E. Sharpless & D. T. Scadden (2006). "Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a." *Nature* 443(7110): 421-426 Jung, Y., J. Song, Y. Shiozawa, J. Wang, Z. Wang, B. Williams, A. Havens, A. Schneider, C.

Ge, R. T. Franceschi, L. K. McCauley, P. H. Krebsbach & R. S. Taichman (2008). "Hematopoietic stem cells regulate mesenchymal stromal cell induction into


Gruver, A. L., L. L. Hudson & G. D. Sempowski (2007). "Immunosenescence of ageing." *J* 

Guba, S. C., C. I. Sartor, L. R. Gottschalk, Y. H. Jing, T. Mulligan & S. G. Emerson (1992).

reverse transcriptase polymerase chain reaction." *Blood* 80(5): 1190-1198 Gupta, P., J. B. McCarthy & C. M. Verfaillie (1996). "Stromal fibroblast heparan sulfate is

Gupta, P., T. R. Oegema, Jr., J. J. Brazil, A. Z. Dudek, A. Slungaard & C. M. Verfaillie (1998).

Hara, H., H. Ohdan, D. Tokita, T. Onoe, W. Zhou & T. Asahara (2003). "Construction of

Harada, M., K. Odaka, K. Kondo, S. Nakao, M. Ueda, K. Matsue, T. Mori & T. Matsuda

Heinrich, M. C., D. C. Dooley, A. C. Freed, L. Band, M. E. Hoatlin, W. W. Keeble, S. T. Peters,

Heissig, B., K. Hattori, S. Dias, M. Friedrich, B. Ferris, N. R. Hackett, R. G. Crystal, P.

Hermanns, P., A. A. Bertuch, T. K. Bertin, B. Dawson, M. E. Schmitt, C. Shaw, B. Zabel & B.

Hermans, M. H., H. Hartsuiker & D. Opstelten (1989). "An in situ study of B-

Hilton, M. J., X. Tu & F. Long (2007). "Tamoxifen-inducible gene deletion reveals a distinct

Holst, J., S. Watson, M. S. Lord, S. S. Eamegdool, D. V. Bax, L. B. Nivison-Smith, A.

induced by concanavalin-A stimulation." *Exp Hematol* 13(9): 963-967 Haylock, D. N. & S. K. Nilsson (2006). "The role of hyaluronic acid in hemopoietic stem cell

factor gene by human stromal cells." *Blood* 82(3): 771-783

hair hypoplasia." *Hum Mol Genet* 14(23): 3723-3740

formation of a multimolecular stem cell niche." *Blood* 92(12): 4641-4651 Gurevitch, O. & I. Fabian (1993). "Ability of the hemopoietic microenvironment in the

"Bone marrow stromal fibroblasts secrete interleukin-6 and granulocytemacrophage colony-stimulating factor in the absence of inflammatory stimulation: demonstration by serum-free bioassay, enzyme-linked immunosorbent assay, and

required for cytokine-mediated ex vivo maintenance of human long-term culture-

"Structurally specific heparan sulfates support primitive human hematopoiesis by

induced bone to maintain the proliferative potential of early hemopoietic

ectopic xenogeneic bone marrow structure associated with persistent multi-lineage mixed chimerism by engraftment of rat bone marrow plugs into mouse kidney

(1985). "Effect of activated lymphocytes on the regulation of hematopoiesis: suppression of in vitro granulopoiesis and erythropoiesis by OKT8+ Ia- T cells

K. V. Silvey, F. S. Ey, D. Kabat & et al. (1993). "Constitutive expression of steel

Besmer, D. Lyden, M. A. Moore, Z. Werb & S. Rafii (2002). "Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release

Lee (2005). "Consequences of mutations in the non-coding RMRP RNA in cartilage-

lymphocytopoiesis in rat bone marrow. Topographical arrangement of terminal deoxynucleotidyl transferase-positive cells and pre-B cells." *J Immunol* 142(1): 67-73

cell type associated with trabecular bone, and direct regulation of PTHrP expression and chondrocyte morphology by Ihh in growth region cartilage." *Dev* 

Kondyurin, L. Ma, A. F. Oberhauser, A. S. Weiss & J. E. Rasko (2010). "Substrate

*Pathol* 211(2): 144-156

initiating cells." *Blood* 87(8): 3229-3236

precursors." *Stem Cells* 11(1): 56-61

biology." *Regen Med* 1(4): 437-445

of kit-ligand." *Cell* 109(5): 625-637

*Biol* 308(1): 93-105

capsules." *Xenotransplantation* 10(3): 259-266

elasticity provides mechanical signals for the expansion of hemopoietic stem and progenitor cells." *Nat Biotechnol* 28(10): 1123-1128


Skeletogenesis and the Hematopoietic Niche 175

Kilborn, S. H., G. Trudel & H. Uhthoff (2002). "Review of growth plate closure compared

Klein, G. (1995). "The extracellular matrix of the hematopoietic microenvironment."

Klein, G., S. Conzelmann, S. Beck, R. Timpl & C. A. Muller (1995). "Perlecan in human bone

Klein, G., C. Kibler, F. Schermutzki, J. Brown, C. A. Muller & R. Timpl (1998). "Cell binding

Kohler, A., V. Schmithorst, M. D. Filippi, M. A. Ryan, D. Daria, M. Gunzer & H. Geiger

Kollet, O., A. Dar, S. Shivtiel, A. Kalinkovich, K. Lapid, Y. Sztainberg, M. Tesio, R. M.

Kong, Y. Y., H. Yoshida, I. Sarosi, H. L. Tan, E. Timms, C. Capparelli, S. Morony, A. J.

Kopp, H. G., S. T. Avecilla, A. T. Hooper & S. Rafii (2005). "The bone marrow vascular niche: home of HSC differentiation and mobilization." *Physiology (Bethesda)* 20: 349-356 Kortesidis, A., A. Zannettino, S. Isenmann, S. Shi, T. Lapidot & S. Gronthos (2005). "Stromal-

Kuijpers, T. W., E. Nannenberg, M. Alders, R. Bredius & R. C. Hennekam (2004).

form bone after transplantation in vivo." *J Bone Miner Res* 12(9): 1335-1347 Kuznetsov, S. A., M. Riminucci, N. Ziran, T. W. Tsutsui, A. Corsi, L. Calvi, H. M.

and of skeletal stem cells in the bone marrow." *J Cell Biol* 167(6): 1113-1122 Kwan, K. M., M. K. Pang, S. Zhou, S. K. Cowan, R. Y. Kong, T. Pfordte, B. R. Olsen, D. O.

component for hematopoietic cells." *Matrix Biol* 14(6): 457-465

*Anim Sci* 41(5): 21-26

307-317

*Experientia* 51(9-10): 914-926

bones." *Blood* 114(2): 290-298

*Nature* 397(6717): 315-323

*J Cell Biol* 136(2): 459-471

progenitor cells." *Nat Med* 12(6): 657-664

marrow stromal stem cells." *Blood* 105(10): 3793-3801

with age at sexual maturity and lifespan in laboratory animals." *Contemp Top Lab* 

marrow: a growth-factor-presenting, but anti-adhesive, extracellular matrix

properties of collagen type XIV for human hematopoietic cells." *Matrix Biol* 16(6):

(2009). "Altered cellular dynamics and endosteal location of aged early hematopoietic progenitor cells revealed by time-lapse intravital imaging in long

Samstein, P. Goichberg, A. Spiegel, A. Elson & T. Lapidot (2006). "Osteoclasts degrade endosteal components and promote mobilization of hematopoietic

Oliveira-dos-Santos, G. Van, A. Itie, W. Khoo, A. Wakeham, C. R. Dunstan, D. L. Lacey, T. W. Mak, W. J. Boyle & J. M. Penninger (1999). "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis."

derived factor-1 promotes the growth, survival, and development of human bone

"Congenital aplastic anemia caused by mutations in the SBDS gene: a rare presentation of Shwachman-Diamond syndrome." *Pediatrics* 114(3): e387-391 Kuznetsov, S. A., P. H. Krebsbach, K. Satomura, J. Kerr, M. Riminucci, D. Benayahu & P. G.

Robey (1997). "Single-colony derived strains of human marrow stromal fibroblasts

Kronenberg, E. Schipani, P. G. Robey & P. Bianco (2004). "The interplay of osteogenesis and hematopoiesis: expression of a constitutively active PTH/PTHrP receptor in osteogenic cells perturbs the establishment of hematopoiesis in bone

Sillence, P. P. Tam & K. S. Cheah (1997). "Abnormal compartmentalization of cartilage matrix components in mice lacking collagen X: implications for function."

osteoblasts thereby participating in the formation of the stem cell niche." *Stem Cells* 26(8): 2042-2051


Jung, Y., J. Wang, A. Havens, Y. Sun, J. Wang, T. Jin & R. S. Taichman (2005). "Cell-to-cell

Jung, Y., J. Wang, A. Schneider, Y. X. Sun, A. J. Koh-Paige, N. I. Osman, L. K. McCauley & R.

Kacena, M. A., C. M. Gundberg & M. C. Horowitz (2006). "A reciprocal regulatory

Kacena, M. A., R. A. Shivdasani, K. Wilson, Y. Xi, N. Troiano, A. Nazarian, C. M. Gundberg,

Kalajzic, Z., H. Li, L. P. Wang, X. Jiang, K. Lamothe, D. J. Adams, H. L. Aguila, D. W. Rowe

Kalinkovich, A., A. Spiegel, S. Shivtiel, O. Kollet, N. Jordaney, W. Piacibello & T. Lapidot

Katayama, Y., M. Battista, W. M. Kao, A. Hidalgo, A. J. Peired, S. A. Thomas & P. S. Frenette

Kawai, M., H. Hattori, K. Yasue, H. Mizutani, M. Ueda, T. Kaneda & T. Hoshino (1994).

bone morphogenetic protein." *Blood Cells* 20(1): 191-199; discussion 200-191 Keller, J. R., J. M. Gooya & F. W. Ruscetti (1996). "Direct synergistic effects of leukemia

hematopoietins that use the gp130 receptor subunit." *Blood* 88(3): 863-869 Khosla, S. (2003). "Parathyroid hormone plus alendronate--a combination that does not add

Kiel, M. J., M. Acar, G. L. Radice & S. J. Morrison (2009). "Hematopoietic stem cells do not depend on N-cadherin to regulate their maintenance." *Cell Stem Cell* 4(2): 170-179 Kiel, M. J., G. L. Radice & S. J. Morrison (2007). "Lack of evidence that hematopoietic stem

Kiel, M. J., O. H. Yilmaz, T. Iwashita, O. H. Yilmaz, C. Terhorst & S. J. Morrison (2005).

Kieslinger, M., S. Hiechinger, G. Dobreva, G. G. Consalez & R. Grosschedl (2010). "Early B

reveal endothelial niches for stem cells." *Cell* 121(7): 1109-1121

possible mechanism for stem cell homing." *Bone* 38(4): 497-508

an osteoprogenitor population." *Bone* 43(3): 501-510

cell egress from bone marrow." *Cell* 124(2): 407-421

up." *N Engl J Med* 349(13): 1277-1279

maintenance." *Cell Stem Cell* 1(2): 204-217

manner." *Cell Stem Cell* 7(4): 496-507

26(8): 2042-2051

*Cytokine* 32(3-4): 155-162

*Bone* 39(5): 978-984

1059-1065

*Bone Miner Res* 19(4): 652-660

osteoblasts thereby participating in the formation of the stem cell niche." *Stem Cells*

contact is critical for the survival of hematopoietic progenitor cells on osteoblasts."

S. Taichman (2006). "Regulation of SDF-1 (CXCL12) production by osteoblasts; a

interaction between megakaryocytes, bone cells, and hematopoietic stem cells."

M. L. Bouxsein, J. A. Lorenzo & M. C. Horowitz (2004). "Megakaryocyte-osteoblast interaction revealed in mice deficient in transcription factors GATA-1 and NF-E2." *J* 

& I. Kalajzic (2008). "Use of an alpha-smooth muscle actin GFP reporter to identify

(2009). "Blood-forming stem cells are nervous: direct and indirect regulation of immature human CD34+ cells by the nervous system." *Brain Behav Immun* 23(8):

(2006). "Signals from the sympathetic nervous system regulate hematopoietic stem

"Development of hemopoietic bone marrow within the ectopic bone induced by

inhibitory factor on hematopoietic progenitor cell growth: comparison with other

cells depend on N-cadherin-mediated adhesion to osteoblasts for their

"SLAM family receptors distinguish hematopoietic stem and progenitor cells and

cell factor 2 regulates hematopoietic stem cell homeostasis in a cell-nonautonomous


Skeletogenesis and the Hematopoietic Niche 177

Mankani, M. H., S. A. Kuznetsov, G. W. Marshall & P. G. Robey (2008). "Creation of new

Mankani, M. H., S. A. Kuznetsov & P. G. Robey (2007). "Formation of hematopoietic

Mansour, A., A. Anginot, S. J. Mancini, C. Schiff, G. F. Carle, A. Wakkach & C. Blin-

Matrosova, V. Y., I. A. Orlovskaya, N. Serobyan & S. K. Khaldoyanidi (2004). "Hyaluronic

Mayack, S. R., J. L. Shadrach, F. S. Kim & A. J. Wagers (2010). "Systemic signals regulate ageing and rejuvenation of blood stem cell niches." *Nature* 463(7280): 495-500 Mazzon, C., A. Anselmo, J. Cibella, C. Soldani, A. Destro, N. Kim, M. Roncalli, S. J. Burden,

Meck, R. A., J. E. Haley & G. Brecher (1973). "Hematopoiesis versus osteogenesis in ectopic

Medici, D., E. M. Shore, V. Y. Lounev, F. S. Kaplan, R. Kalluri & B. R. Olsen (2010).

Medvinsky, A. & E. Dzierzak (1996). "Definitive hematopoiesis is autonomously initiated by

Mendez-Ferrer, S., D. Lucas, M. Battista & P. S. Frenette (2008). "Haematopoietic stem cell release is regulated by circadian oscillations." *Nature* 452(7186): 442-447 Mendez-Ferrer, S., T. V. Michurina, F. Ferraro, A. R. Mazloom, B. D. Macarthur, S. A. Lira,

Merzaban, J. S., M. M. Burdick, S. Z. Gadhoum, N. M. Dagia, J. T. Chu, R. C. Fuhlbrigge & R.

Mignini, F., V. Streccioni & F. Amenta (2003). "Autonomic innervation of immune organs and neuroimmune modulation." *Auton Autacoid Pharmacol* 23(1): 1-25 Miharada, K., T. Hiroyama, K. Sudo, I. Danjo, T. Nagasawa & Y. Nakamura (2008).

Moreaux, J., F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos,

Moreaux, J., A. C. Sprynski, S. R. Dillon, K. Mahtouk, M. Jourdan, A. Ythier, P. Moine, N.

monocyte/macrophage lineage cells." *J Cell Physiol* 215(2): 526-537

plasmablastic signature." *Blood* 106(3): 1021-1030

HA/TCP suspensions." *Tissue Eng Part A* 14(12): 1949-1958

hematopoietic stem cell niche." *Blood* 118(10): 2733-2742

bone marrow transplants." *Blood* 42(5): 661-669

the AGM region." *Cell* 86(6): 897-906

critical cell density." *Exp Hematol* 35(6): 995-1004

marrow." *Cell Res* 21(7): 1102-1115

16(12): 1400-1406

466(7308): 829-834

1783

administration." *Stem Cells* 22(4): 544-555

bone by the percutaneous injection of human bone marrow stromal cell and

territories and bone by transplanted human bone marrow stromal cells requires a

Wakkach (2011). "Osteoclast activity modulates B-cell development in the bone

acid facilitates the recovery of hematopoiesis following 5-fluorouracil

M. L. Dustin, A. Sarukhan & A. Viola (2011). "The critical role of agrin in the

"Conversion of vascular endothelial cells into multipotent stem-like cells." *Nat Med*

D. T. Scadden, A. Ma'ayan, G. N. Enikolopov & P. S. Frenette (2010). "Mesenchymal and haematopoietic stem cells form a unique bone marrow niche." *Nature*

Sackstein (2011). "Analysis of glycoprotein E-selectin ligands on human and mouse marrow cells enriched for hematopoietic stem/progenitor cells." *Blood* 118(7): 1774-

"Lipocalin 2-mediated growth suppression is evident in human erythroid and

E. Jourdan, A. Jauch, E. Legouffe, M. Moos, G. Fiol, H. Goldschmidt, J. F. Rossi, D. Hose & B. Klein (2005). "The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a

Robert, E. Jourdan, J. F. Rossi & B. Klein (2009). "APRIL and TACI interact with


Kwon, K. R., J. Y. Ahn, M. S. Kim, J. Y. Jung, J. H. Lee & I. H. Oh (2010). "Disruption of bis

Lanotte, M., D. Metcalf & T. M. Dexter (1982). "Production of monocyte/macrophage

Lapid, K., Y. Vagima, O. Kollet & T. Lapidot (2008). "Egress and mobilization of

Larsson, J., M. Ohishi, B. Garrison, M. Aspling, V. Janzen, G. B. Adams, M. Curto, A. I.

Lefebvre, V. & P. Smits (2005). "Transcriptional control of chondrocyte fate and differentiation." *Birth Defects Res Part C: Embryo Today: Reviews* 75(3): 200-212 Levesque, J. P. & P. J. Simmons (1999). "Cytoskeleton and integrin-mediated adhesion

Levesque, J. P., Y. Takamatsu, S. K. Nilsson, D. N. Haylock & P. J. Simmons (2001). "Vascular

Li, W., S. A. Johnson, W. C. Shelley & M. C. Yoder (2004). "Hematopoietic stem cell

Lo Celso, C., H. E. Fleming, J. W. Wu, C. X. Zhao, S. Miake-Lye, J. Fujisaki, D. Cote, D. W.

Mackie, E. J., Y. A. Ahmed, L. Tatarczuch, K. S. Chen & M. Mirams (2008). "Endochondral

Maes, C., T. Kobayashi, M. K. Selig, S. Torrekens, S. I. Roth, S. Mackem, G. Carmeliet & H.

Majumdar, M. K., M. A. Thiede, S. E. Haynesworth, S. P. Bruder & S. L. Gerson (2000).

stromal and osteogenic lineages." *J Hematother Stem Cell Res* 9(6): 841-848 Mangan, K. F., G. Chikkappa, L. Z. Bieler, W. B. Scharfman & D. R. Parkinson (1982).

*Cells* 28(2): 268-278

*Stem Cell* 3(2): 221-227

*Exp Hematol* 32(12): 1226-1237

*Biochem Cell Biol* 40(1): 46-62

19(2): 329-344

*Blood* 59(5): 990-996

586

stroma." *J Cell Physiol* 112(1): 123-127

hematopoietic stem and progenitor cells."

colony-stimulating factor." *Blood* 98(5): 1289-1297

CFUc in the normal mouse femur." *Blood* 46(1): 65-72

leads to the deterioration of the vascular niche for hematopoietic stem cells." *Stem* 

colony-stimulating factor by preadipocyte cell lines derived from murine marrow

McClatchey, E. Schipani & D. T. Scadden (2008). "Nf2/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture." *Cell* 

signaling in human CD34+ hemopoietic progenitor cells." *Exp Hematol* 27(4): 579-

cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte

repopulating ability can be maintained in vitro by some primary endothelial cells."

Rowe, C. P. Lin & D. T. Scadden (2009). "Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche." *Nature* 457(7225): 92-96 Lord, B. I., N. G. Testa & J. H. Hendry (1975). "The relative spatial distributions of CFUs and

ossification: how cartilage is converted into bone in the developing skeleton." *Int J* 

M. Kronenberg (2010). "Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels." *Dev Cell*

"Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward

"Regulation of human blood erythroid burst-forming unit (BFU-E) proliferation by T-lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies."


Skeletogenesis and the Hematopoietic Niche 179

O'Connor, B. P., V. S. Raman, L. D. Erickson, W. J. Cook, L. K. Weaver, C. Ahonen, L. L. Lin,

Ohneda, O., C. Fennie, Z. Zheng, C. Donahue, H. La, R. Villacorta, B. Cairns & L. A. Lasky

Ohta, M., T. Sakai, Y. Saga, S. Aizawa & M. Saito (1998). "Suppression of hematopoietic

Omatsu, Y., T. Sugiyama, H. Kohara, G. Kondoh, N. Fujii, K. Kohno & T. Nagasawa (2010).

Osmond, D. G. (1990). "B cell development in the bone marrow." *Semin Immunol* 2(3): 173-

Ottersbach, K. & E. Dzierzak (2005). "The murine placenta contains hematopoietic stem cells

Patt, H. M., M. A. Maloney & M. L. Flannery (1982). "Hematopoietic microenvironment

Peerani, R. & P. W. Zandstra (2010). "Enabling stem cell therapies through synthetic stem

Peled, A., V. Grabovsky, L. Habler, J. Sandbank, F. Arenzana-Seisdedos, I. Petit, H. Ben-Hur,

Petit, I., M. Szyper-Kravitz, A. Nagler, M. Lahav, A. Peled, L. Habler, T. Ponomaryov, R. S.

Petrini, M., S. Pacini, L. Trombi, R. Fazzi, M. Montali, S. Ikehara & N. G. Abraham (2009).

Pfeiffer, C. A. (1948). "Development of bone from transplanted marrow in mice." *Anat Rec*

Pilia, G., R. M. Hughes-Benzie, A. MacKenzie, P. Baybayan, E. Y. Chen, R. Huber, G. Neri,

Ponomaryov, T., A. Peled, I. Petit, R. S. Taichman, L. Habler, J. Sandbank, F. Arenzana-

of long-lived bone marrow plasma cells." *J Exp Med* 199(1): 91-98

activity in tenascin-C-deficient mice." *Blood* 91(11): 4074-4083

within the vascular labyrinth region." *Dev Cell* 8(3): 377-387

and progenitor cell niche." *Immunity* 33(3): 387-399

cell-niche engineering." *J Clin Invest* 120(1): 60-70

and up-regulating CXCR4." *Nat Immunol* 3(7): 687-694

bone marrow." *Stem Cells Dev* 18(6): 857-866

672

908-919

180

*Exp Hematol* 10(9): 738-742

104(9): 1199-1211

102(2): 225-243

241-247

1331-1339

hematopoietic stem cells in the midgestation mouse embryo." *Immunity* 16(5): 661-

G. T. Mantchev, R. J. Bram & R. J. Noelle (2004). "BCMA is essential for the survival

(1998). "Hematopoietic stem cell maintenance and differentiation are supported by embryonic aorta-gonad-mesonephros region-derived endothelium." *Blood* 92(3):

"The essential functions of adipo-osteogenic progenitors as the hematopoietic stem

transfer by stromal fibroblasts derived from bone marrow varying in cellularity."

T. Lapidot & R. Alon (1999). "The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow." *J Clin Invest*

Taichman, F. Arenzana-Seisdedos, N. Fujii, J. Sandbank, D. Zipori & T. Lapidot (2002). "G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1

"Identification and purification of mesodermal progenitor cells from human adult

A. Cao, A. Forabosco & D. Schlessinger (1996). "Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome." *Nat Genet* 12(3):

Seisdedos, A. Magerus, A. Caruz, N. Fujii, A. Nagler, M. Lahav, M. Szyper-Kravitz, D. Zipori & T. Lapidot (2000). "Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function." *J Clin Invest* 106(11):

syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop." *Eur J Haematol* 83(2): 119-129


Morikawa, S., Y. Mabuchi, Y. Kubota, Y. Nagai, K. Niibe, E. Hiratsu, S. Suzuki, C. Miyauchi-

Morrison, S. J. & A. C. Spradling (2008). "Stem cells and niches: mechanisms that promote

Muguruma, Y., T. Yahata, H. Miyatake, T. Sato, T. Uno, J. Itoh, S. Kato, M. Ito, T. Hotta & K.

Murayama, E., K. Kissa, A. Zapata, E. Mordelet, V. Briolat, H. F. Lin, R. I. Handin & P.

Nagasawa, T., S. Hirota, K. Tachibana, N. Takakura, S. Nishikawa, Y. Kitamura, N. Yoshida,

Nagasawa, T., H. Kikutani & T. Kishimoto (1994). "Molecular cloning and structure of a pre-B-cell growth-stimulating factor." *Proc Natl Acad Sci U S A* 91(6): 2305-2309 Naiyer, A. J., D. Y. Jo, J. Ahn, R. Mohle, M. Peichev, G. Lam, R. L. Silverstein, M. A. Moore &

Nakamura, E., M. T. Nguyen & S. Mackem (2006). "Kinetics of tamoxifen-regulated Cre

windows along the proximodistal limb skeleton." *Dev Dyn* 235(9): 2603-2612 Nathan, D. G., L. Chess, D. G. Hillman, B. Clarke, J. Breard, E. Merler & D. E. Housman

Naveiras, O., V. Nardi, P. L. Wenzel, P. V. Hauschka, F. Fahey & G. Q. Daley (2009). "Bone-

Nilsson, S. K., M. S. Dooner, C. Y. Tiarks, H. U. Weier & P. J. Quesenberry (1997). "Potential

Nilsson, S. K., H. M. Johnston & J. A. Coverdale (2001). "Spatial localization of transplanted

North, T. E., M. F. de Bruijn, T. Stacy, L. Talebian, E. Lind, C. Robin, M. Binder, E. Dzierzak

stem cell maintenance throughout life." *Cell* 132(4): 598-611

bone marrow compartment." *Blood* 107(5): 1878-1887

development." *Nat Rev Immunol* 6(2): 107-116

mediated by E-selectin." *Blood* 94(12): 4011-4019

microenvironment." *Nature* 460(7252): 259-263

in vitro." *J Exp Med* 147(2): 324-339

model." *Blood* 89(11): 4013-4020

97(8): 2293-2299

382(6592): 635-638

loop." *Eur J Haematol* 83(2): 119-129

marrow." *J Exp Med* 206(11): 2483-2496

syndecan-1 on the surface of multiple myeloma cells to form an essential survival

Hara, N. Nagoshi, T. Sunabori, S. Shimmura, A. Miyawaki, T. Nakagawa, T. Suda, H. Okano & Y. Matsuzaki (2009). "Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone

Ando (2006). "Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine

Herbomel (2006). "Tracing hematopoietic precursor migration to successive hematopoietic organs during zebrafish development." *Immunity* 25(6): 963-975 Nagasawa, T. (2006). "Microenvironmental niches in the bone marrow required for B-cell

H. Kikutani & T. Kishimoto (1996). "Defects of B-cell lymphopoiesis and bonemarrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1." *Nature*

S. Rafii (1999). "Stromal derived factor-1-induced chemokinesis of cord blood CD34(+) cells (long-term culture-initiating cells) through endothelial cells is

activity in mice using a cartilage-specific CreER(T) to assay temporal activity

(1978). "Human erythroid burst-forming unit: T-cell requirement for proliferation

marrow adipocytes as negative regulators of the haematopoietic

and distribution of transplanted hematopoietic stem cells in a nonablated mouse

hemopoietic stem cells: inferences for the localization of stem cell niches." *Blood*

& N. A. Speck (2002). "Runx1 expression marks long-term repopulating

hematopoietic stem cells in the midgestation mouse embryo." *Immunity* 16(5): 661- 672


Skeletogenesis and the Hematopoietic Niche 181

Sagar, B. M., S. Rentala, P. N. Gopal, S. Sharma & A. Mukhopadhyay (2006). "Fibronectin

Sanchez, M. J., A. Holmes, C. Miles & E. Dzierzak (1996). "Characterization of the first

Schmid, T. M. & T. F. Linsenmayer (1985). "Immunohistochemical localization of short chain cartilage collagen (type X) in avian tissues." *J Cell Biol* 100(2): 598-605 Schofield, R. (1978). "The relationship between the spleen colony-forming cell and the

Schwaller, J., P. Schneider, P. Mhawech-Fauceglia, T. McKee, S. Myit, T. Matthes, J. Tschopp,

Schweitzer, K. M., A. M. Drager, P. van der Valk, S. F. Thijsen, A. Zevenbergen, A. P.

Shackney, S. E., S. S. Ford & A. B. Wittig (1975). "Kinetic-microarchitectural correlations in

Siczkowski, M., D. Clarke & M. Y. Gordon (1992). "Binding of primitive hematopoietic

Siebertz, B., G. Stocker, Z. Drzeniek, S. Handt, U. Just & H. D. Haubeck (1999). "Expression

Sipkins, D. A., X. Wei, J. W. Wu, J. M. Runnels, D. Cote, T. K. Means, A. D. Luster, D. T.

Spiegel, A., A. Kalinkovich, S. Shivtiel, O. Kollet & T. Lapidot (2008). "Stem cell regulation

Spiegel, A., S. Shivtiel, A. Kalinkovich, A. Ludin, N. Netzer, P. Goichberg, Y. Azaria, I.

Spiegel, A., E. Zcharia, Y. Vagima, T. Itkin, A. Kalinkovich, A. Dar, O. Kollet, N. Netzer, K.

microenvironment." *Cell* 131(2): 324-336

*Biophys Res Commun* 350(4): 1000-1005

aggressiveness." *Blood* 109(1): 331-338

*Biochem J* 344 (Pt 3): 937-943

niche." *Blood* 115(13): 2592-2600

microenvironment." *Cell Stem Cell* 3(5): 484-492

haemopoietic stem cell." *Blood Cells* 4(1-2): 7-25

of hematopoietic tissues." *Am J Pathol* 148(1): 165-175

the bone marrow of the mouse." *Cell Tissue Kinet* 8(6): 505-516

*Immunity* 5(6): 513-525

919

1131

osteoprogenitors in bone marrow sinusoids can organize a hematopoietic

and laminin enhance engraftibility of cultured hematopoietic stem cells." *Biochem* 

definitive hematopoietic stem cells in the AGM and liver of the mouse embryo."

O. Donze, F. A. Le Gal & B. Huard (2007). "Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma

Theijsmeijer, C. E. van der Schoot & M. M. Langenhuijsen (1996). "Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells

progenitor cells to marrow stromal cells involves heparan sulfate." *Blood* 80(4): 912-

of glypican-4 in haematopoietic-progenitor and bone-marrow-stromal cells."

Scadden & C. P. Lin (2005). "In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment." *Nature* 435(7044): 969-973 Song, J., M. J. Kiel, Z. Wang, J. Wang, R. S. Taichman, S. J. Morrison & P. H. Krebsbach

(2010). "An in vivo model to study and manipulate the hematopoietic stem cell

via dynamic interactions of the nervous and immune systems with the

Resnick, I. Hardan, H. Ben-Hur, A. Nagler, M. Rubinstein & T. Lapidot (2007). "Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling." *Nat Immunol* 8(10): 1123-

Golan, I. Shafat, N. Ilan, A. Nagler, I. Vlodavsky & T. Lapidot (2008). "Heparanase regulates retention and proliferation of primitive Sca-1+/c-Kit+/Lin- cells via modulation of the bone marrow microenvironment." *Blood* 111(10): 4934-4943


Purton, L. E., S. Dworkin, G. H. Olsen, C. R. Walkley, S. A. Fabb, S. J. Collins & P. Chambon

Rafii, S., R. Mohle, F. Shapiro, B. M. Frey & M. A. Moore (1997). "Regulation of hematopoiesis by microvascular endothelium." *Leuk Lymphoma* 27(5-6): 375-386 Rafii, S., F. Shapiro, R. Pettengell, B. Ferris, R. L. Nachman, M. A. Moore & A. S. Asch (1995).

Rafii, S., F. Shapiro, J. Rimarachin, R. L. Nachman, B. Ferris, B. Weksler, M. A. Moore & A. S.

endothelial cells: hematopoietic progenitor cell adhesion." *Blood* 84(1): 10-19 Roach, H. I. (1992). "Trans-differentiation of hypertrophic chondrocytes into cells capable of

Roach, H. I. & J. Erenpreisa (1996). "The phenotypic switch from chondrocytes to bone-

Roach, H. I., J. Erenpreisa & T. Aigner (1995). "Osteogenic differentiation of hypertrophic

Roberts, R., J. Gallagher, E. Spooncer, T. D. Allen, F. Bloomfield & T. M. Dexter (1988).

Rodgers, K. D., J. D. San Antonio & O. Jacenko (2008). "Heparan sulfate proteoglycans: A GAGgle of skeletal-hematopoietic regulators." *Dev Dyn* 237(10): 2622-2642 Rosati, R., G. S. Horan, G. J. Pinero, S. Garofalo, D. R. Keene, W. A. Horton, E. Vuorio, B. de

Rossi, D. J., D. Bryder, J. M. Zahn, H. Ahlenius, R. Sonu, A. J. Wagers & I. L. Weissman

Rossi, D. J., C. H. Jamieson & I. L. Weissman (2008). "Stems cells and the pathways to aging

Rouleau, M. F., J. Mitchell & D. Goltzman (1990). "Characterization of the major parathyroid

Ryan, D. H., B. L. Nuccie, C. N. Abboud & J. M. Winslow (1991). "Vascular cell adhesion

Sacchetti, B., A. Funari, S. Michienzi, S. Di Cesare, S. Piersanti, I. Saggio, E. Tagliafico, S.

cultured bone marrow adherent cells." *J Clin Invest* 88(3): 995-1004

development in type X collagen-null mice." *Nat Genet* 8(2): 129-135

producing a mineralized bone matrix." *Bone Miner* 19(1): 1-20

haemopoiesis." *Nature* 332(6162): 376-378

*Acad Sci U S A* 102(26): 9194-9199

and cancer." *Cell* 132(4): 681-696

5(10): 1043-1053

stem cell self-renewal and differentiation." *J Exp Med* 203(5): 1283-1293 Raaijmakers, M. H., S. Mukherjee, S. Guo, S. Zhang, T. Kobayashi, J. A. Schoonmaker, B. L.

852-857

86(9): 3353-3363

35(1-4): 85-91

483-494

(2006). "RARgamma is critical for maintaining a balance between hematopoietic

Ebert, F. Al-Shahrour, R. P. Hasserjian, E. O. Scadden, Z. Aung, M. Matza, M. Merkenschlager, C. Lin, J. M. Rommens & D. T. Scadden (2010). "Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia." *Nature* 464(7290):

"Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors." *Blood*

Asch (1994). "Isolation and characterization of human bone marrow microvascular

forming cells involves asymmetric cell division and apoptosis." *Connect Tissue Res*

chondrocytes involves asymmetric cell divisions and apoptosis." *J Cell Biol* 131(2):

"Heparan sulphate bound growth factors: a mechanism for stromal cell mediated

Crombrugghe & R. R. Behringer (1994). "Normal long bone growth and

(2005). "Cell intrinsic alterations underlie hematopoietic stem cell aging." *Proc Natl* 

hormone target cell in the endosteal metaphysis of rat long bones." *J Bone Miner Res*

molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to

Ferrari, P. G. Robey, M. Riminucci & P. Bianco (2007). "Self-renewing

osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment." *Cell* 131(2): 324-336


Skeletogenesis and the Hematopoietic Niche 183

Trinchieri, G., M. Murphy & B. Perussia (1987). "Regulation of hematopoiesis by T lymphocytes and natural killer cells." *Crit Rev Oncol Hematol* 7(3): 219-265 Verfaillie, C. M. (1993). "Soluble factor(s) produced by human bone marrow stroma increase

Visnjic, D., I. Kalajzic, G. Gronowicz, H. L. Aguila, S. H. Clark, A. C. Lichtler & D. W. Rowe

Visnjic, D., Z. Kalajzic, D. W. Rowe, V. Katavic, J. Lorenzo & H. L. Aguila (2004).

Viviano, B. L., L. Silverstein, C. Pflederer, S. Paine-Saunders, K. Mills & S. Saunders (2005).

Walkley, C. R., G. H. Olsen, S. Dworkin, S. A. Fabb, J. Swann, G. A. McArthur, S. V.

Walkley, C. R., J. M. Shea, N. A. Sims, L. E. Purton & S. H. Orkin (2007). "Rb regulates

Wei, L., K. Kanbe, M. Lee, X. Wei, M. Pei, X. Sun, R. Terek & Q. Chen (2010). "Stimulation of

Weinstein, R., M. A. Riordan, K. Wenc, S. Kreczko, M. Zhou & N. Dainiak (1989). "Dual role

Weiss, L. (1976). "The hematopoietic microenvironment of the bone marrow: an

Wittig, O., J. Paez-Cortez & J. Cardier (2009). "Liver Sinusoidal Endothelial Cells Promote B Lymphopoiesis from Primitive Hematopoietic Cells." *Stem Cells Dev*  Wolf, N. S. (1979). "The haemopoietic microenvironment." *Clin Haematol* 8(2): 469-500

Wolf, N. S. & J. J. Trentin (1968). "Hemopoietic colony studies. V. Effect of hemopoietic

Wu, J. Y., L. E. Purton, S. J. Rodda, M. Chen, L. S. Weinstein, A. P. McMahon, D. T. Scadden

Xie, Y., T. Yin, W. Wiegraebe, X. C. He, D. Miller, D. Stark, K. Perko, R. Alexander, J.

organ stroma on differentiation of pluripotent stem cells." *J Exp Med* 127(1): 205-214

& H. M. Kronenberg (2008). "Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent signaling pathways." *Proc Natl Acad Sci U S A*

Schwartz, J. C. Grindley, J. Park, J. S. Haug, J. P. Wunderlich, H. Li, S. Zhang, T.

of fibronectin in hematopoietic differentiation." *Blood* 73(1): 111-116

ultrastructural study of the stroma in rats." *Anat Rec* 186(2): 161-184

*J Clin Pathol* 55(9): 693-698

*Blood* 103(9): 3258-3264

236-245

105(44): 16976-16981

mice." *J Bone Miner Res* 16(12): 2222-2231

haematopoietic stem cells." *Nat Cell Biol* 7(2): 172-178

receptor gamma deficiency." *Cell* 129(6): 1097-1110

microenvironment." *Cell* 129(6): 1081-1095

cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation." *Blood* 82(7): 2045-2053 Verma, S., J. H. Rajaratnam, J. Denton, J. A. Hoyland & R. J. Byers (2002). "Adipocytic

proportion of bone marrow is inversely related to bone formation in osteoporosis."

(2001). "Conditional ablation of the osteoblast lineage in Col2.3deltatk transgenic

"Hematopoiesis is severely altered in mice with an induced osteoblast deficiency."

"Altered hematopoiesis in glypican-3-deficient mice results in decreased osteoclast differentiation and a delay in endochondral ossification." *Dev Biol* 282(1): 152-162 Walkley, C. R., M. L. Fero, W. M. Chien, L. E. Purton & G. A. McArthur (2005). "Negative

cell-cycle regulators cooperatively control self-renewal and differentiation of

Westmoreland, P. Chambon, D. T. Scadden & L. E. Purton (2007). "A microenvironment-induced myeloproliferative syndrome caused by retinoic acid

interactions between hematopoietic stem cells and their bone marrow

chondrocyte hypertrophy by chemokine stromal cell-derived factor 1 in the chondro-osseous junction during endochondral bone formation." *Dev Biol* 341(1):


Spooncer, E., J. T. Gallagher, F. Krizsa & T. M. Dexter (1983). "Regulation of haemopoiesis in

stimulation of haemopoiesis by beta-D-xylosides." *J Cell Biol* 96(2): 510-514 Spranger, J., G. K. Hinkel, H. Stoss, W. Thoenes, D. Wargowski & F. Zepp (1991). "Schimke

Srinivas, V. & I. M. Shapiro (2006). "Chondrocytes embedded in the epiphyseal growth

Sugiyama, T., H. Kohara, M. Noda & T. Nagasawa (2006). "Maintenance of the

Sweeney, E., M. Campbell, K. Watkins, C. A. Hunter & O. Jacenko (2008). "Altered

Sweeney, E., D. Roberts, T. Corbo & O. Jacenko (2010). "Congenic mice confirm that collagen X is required for proper hematopoietic development." *PLoS One* 5(3): e9518 Taichman, R. S. & S. G. Emerson (1994). "Human osteoblasts support hematopoiesis through

Taichman, R. S., M. J. Reilly & S. G. Emerson (1996). "Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures." *Blood* 87(2): 518-524 Taichman, R. S., M. J. Reilly, R. S. Verma & S. G. Emerson (1997). "Augmented production of

Tavassoli, M. (1984). "Hemopoiesis in ectopically implanted bone marrow." *Kroc Found Ser*

Tavassoli, M. & W. H. Crosby (1968). "Transplantation of marrow to extramedullary sites."

Tavassoli, M. & R. Khademi (1980). "The origin of hemopoietic cells in ectopic implants of

Tavassoli, M., A. Maniatis & W. H. Crosby (1974). "Induction of sustained hemopoiesis in

Tavassoli, M. & L. Weiss (1971). "The structure of developing bone marrow sinuses in extramedullary autotransplant of the marrow in rats." *Anat Rec* 171(4): 477-494 Teixido, J., M. E. Hemler, J. S. Greenberger & P. Anklesaria (1992). "Role of beta 1 and beta 2

Tokoyoda, K., T. Egawa, T. Sugiyama, B. I. Choi & T. Nagasawa (2004). "Cellular niches

Touw, I. & B. Lowenberg (1983). "No stimulative effect of adipocytes on hematopoiesis in

Trentin, J. J. (1971). "Determination of bone marrow stem cell differentiation by stromal hemopoietic inductive microenvironments (HIM)." *Am J Pathol* 65(3): 621-628

long-term human bone marrow cultures." *Blood* 61(4): 770-774

integrins in the adhesion of human CD34hi stem cells to bone marrow stroma." *J* 

controlling B lymphocyte behavior within bone marrow during development."

marrow stromal cell niches." *Immunity* 25(6): 977-988

bone marrow cells in vitro." *Blood* 89(4): 1165-1172

spleen and marrow." *Experientia* 36(9): 1126-1127

responses." *Dev Dyn* 237(10): 2693-2704

119(1 ( Pt 1)): 64-72

1682

18: 31-54

*Science* 161(836): 54-56

*Clin Invest* 90(2): 358-367

*Immunity* 20(6): 707-718

fatty marrow." *Blood* 43(1): 33-38

*Autophagy* 2(3): 215-216

long-term bone marrow cultures. IV. Glycosaminoglycan synthesis and the

immuno-osseous dysplasia: a newly recognized multisystem disease." *J Pediatr*

plates of long bones undergo autophagy prior to the induction of osteogenesis."

hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone

endochondral ossification in collagen X mouse models leads to impaired immune

the production of granulocyte colony-stimulating factor." *J Exp Med* 179(5): 1677-

interleukin-6 by normal human osteoblasts in response to CD34+ hematopoietic


**9** 

*The Netherlands* 

**Molecular Mechanisms Underlying Bone** 

*Department of Hematology and Erasmus MC Stem Cell Institute for* 

Aysegul Ocal Sahin and Miranda Buitenhuis

*Regenerative Medicine, Erasmus MC, Rotterdam,* 

**Marrow Homing of Hematopoietic Stem Cells** 

The formation of blood cells, also called hematopoiesis, is a complex process that occurs in the bone marrow and depends on correct regulation of hematopoietic cell fate decisions. Aberrant regulation of hematopoiesis can result in the development of severe malignant and non-malignant hematological disorders, including leukemia. Hematopoietic stem cell transplantation is the most powerful treatment modality for a large number of those malignancies. Successful hematopoietic recovery after transplantation depends on homing of hematopoietic stem cells to the bone marrow and subsequent lodging of those cells in the

Homing is a rapid, coordinated process in which circulating hematopoietic stem and progenitor cells actively enter the bone marrow within a few hours after transplantation (Figure 1). Rolling and firm adhesion of those cells to endothelial cells in small marrow sinusoids is followed by trans-endothelial migration across the endothelium/extracellular matrix barrier. Finally, in irradiated recipients, hematopoietic stem cells anchor to their specialized niches within the bone marrow compartment near osteoblasts and initiate longterm repopulation (Lo Celso et al., 2009). In absence of available niches in, for example, nonirradiated recipients, HSCs tend to be more randomly distributed throughout the bone marrow (Lo Celso et al., 2009). Since the first bone marrow transplantation decades ago, research has focused on understanding the mechanisms underlying homing of hematopoietic stem cells to the bone marrow. This chapter will focus on recent studies that have extended our understanding of the molecular mechanisms underlying adhesion,

A first step in the process of bone marrow homing is initial tethering and rolling of hematopoietic stem and progenitor cells along the endothelial wall of blood vessels. It has been demonstrated that selectins play an important role in bone marrow homing of hematopoietic stem and progenitor cells by regulating these processes. Intravital microscopy in bone marrow sinoids and venules of mice deficient for individual selectins revealed that rolling of hematopoietic progenitor cells involves both P and E-selectin, but not L-selectin (Mazo et al.,

migration and bone marrow homing of hematopoietic stem cells.

**2. Selectins and bone marrow homing** 

**1. Introduction** 

bone marrow microenvironment.

Johnson, R. A. Feldman & L. Li (2009). "Detection of functional haematopoietic stem cell niche using real-time imaging." *Nature* 457(7225): 97-101

